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OSTEOCHONDRAL ALLOGRAFT PRESERVATION IN A SERUM-
FREE CHEMICALLY-DEFINED MEDIA 
Joseph T. Garrity 
Dr. James L. Cook, Thesis Supervisor 
 
ABSTRACT 
 
 
 
Articular cartilage has a very limited capacity as compared to other biological tissues to 
repair and regenerate because of its avascular nature. Chronic degradation of articular 
cartilage may result in osteoarthritis, the most common debilitating disease worldwide. In 
order to alleviate severe pain symptoms and dysfunction associated with osteoarthritis, 
treatment strategies to replace rather than repair the tissue have been developed. 
Osteochondral allografts (OCAs) allow the transplantation of whole cartilage tissue into a 
defect with viable cells, or chondrocytes that will maintain the cartilage matrix. Fresh 
OCAs have demonstrated greater than 75% clinical success in the treatment of articular 
cartilage lesions. Currently allografts are stored at 4°C and used within 28 days, however, 
FDA-mandated disease testing requires 14 days of screening which decreases the 
effective window for implantation to 14 days. The purpose of this study was to evaluate 
OCAs stored up to 56 days in a Control (DMEM supplemented with ITS, Sodium 
Pyruvate, L-ascorbic acid, and MEM Non-essential amino acids) and Test (DMEM 
xviii 
 
supplemented ITS+, Sodium Pyruvate, L-ascorbic acid, MEM Non-Essential amino 
acids, dexamethasone, boron, and TGF-β3) media preparation at 4°C and 37°C. Media 
was changed and collected every 7 days. At Days 0, 28, and 56, full thickness cartilage 
was evaluated for cell viability, GAG and HP content, and histologic evaluation. Media 
was collected at Days 7, 14, 21, 28, 35, 42, 49, and 56 for GAG content of the media, a 
measure of GAG release from tissue. Media collected on Days 7, 28, and 56 was also 
evaluated for NO, PGE2, MMP, and cytokine content. Cell viability as well as tissue 
GAG and HP content were maintained at Day 0 levels up to Day 56 in the 37°C Control 
media. GAG release of tissues at 37°C indicated active metabolism in the tissue. The 
profile of cytokines released during storage by OCAs stored in the 37°C Control media 
may be a preliminary step towards a screening protocol for testing OCA viability during 
storage. Our work showed that storage in a serum-free chemically-defined media at 37°C 
can maintain OCAs \ better than the current tissue banking protocol for storage.  
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CHAPTER 1: LITERATURE REVIEW 
 
 
Articular cartilage pathology is a common finding in the orthopedic world and 
these lesions have a very limited capacity to heal. Curl et al. looked at records from 
31,516 knee arthroscopies and found chondral lesions in 63% of the arthroscopies 
performed.
1
 Another study, a prospective cohort examining 1,000 patients that underwent 
knee arthroscopy, found chondral or osteochondral lesions in 61% of these patients.
2
 In a 
retrospective study from Poland, 25,124 arthroscopies of the knee were evaluated and 
cartilage lesions were seen in 60% of these operations.
3
 In 993 patients with a median age 
of 35 years, articular cartilage pathology was found in 66% of their knees during 
arthroscopy. The most commonly reported activity among these patients was sports 
participation.
4
 A viable treatment option is needed for these patients, many of whom are 
young and active individuals, who are at a higher risk for developing OA later in life 
because of these chondral lesions. Osteoarthritis (OA) is a leading cause of disability in 
the United States with an estimated 27 million people affected by this disease.
5
 It also 
represents a huge burden in cost with associated treatment costs exceeding $60 billion 
annually.
5
 
Articular cartilage injuries are difficult to treat because they have limited healing 
ability.
6
 Articular cartilage injuries can be classified three different ways; cartilage matrix 
and cell injuries, chondral defects, and injuries that extend into the subchondral bone.
7
 
Chondrocytes are usually able to restore cell matrix proteoglycan in injuries that only 
2 
 
disrupt a portion of the cartilage matrix.
8
 The natural response to chondral injuries is 
limited by the lack of blood vessels and reparative cells in articular cartilage but can 
sometimes be repaired in a biologically appropriate manner. Lastly, injuries that extend 
into the subchondral bone cause hemorrhage and the formation of a fibrin clot. The fibrin 
acts as a scaffold for repair.
9
 Inconsistency is a major problem in the biological repair of 
articular cartilage and many times the repair tissue that fills this defect does not maintain 
the mechanical properties of native hyaline cartilage.
10
 This tissue is commonly classified 
as hyaline-like or fibrocartilage with inferior mechanical properties to the native 
cartilage.
7
 The aim of this thesis is to investigate a new culture media for the storage of 
osteochondral allografts. 
Other treatment options for articular cartilage defects 
The primary treatment for chondral lesions is typically arthroscopic lavage and 
debridement.
11
 Symptomatic improvement of joint pain and function was noted in most 
patients after undergoing these procedures.
12,13
 These two procedures remove loose 
cartilage and debris yet do not repair the damaged articular cartilage or prevent the 
advancement of disease. Therefore they are unsatisfactory for a long term solution. 
Unfortunately, it has also been shown that arthroscopic lavage and debridement do not 
improve pain or function compared to placebo arthroscopy.
14
 
The microfracture technique was first introduced in 1997 and showed good functional 
improvement in an eleven year follow-up.
15
 Unfortunately, the defect is not replaced with 
hyaline cartilage after the procedure but rather filled with fibrocartilage.
16
 Also, 
3 
 
significant deterioration in clinical outcome has been seen after eighteen months.
17
 
Results from this procedure are not satisfactory to be a long term solution. 
Osteochondral autografting has shown some promise in the treatment of articular 
cartilage defects, especially small defects. However, differences in thickness, donor-site 
morbidity, and donor-recipient structural differences are complications with using this 
procedure that decrease the effectiveness of this procedure.
18
 In a recent study using 
sheep this procedure resulted in the rapid degeneration of the transplanted cartilage as 
well as chondrocytes near the repair site.
19
 There are currently not enough long term 
studies evaluating the efficacy of this procedure. 
Many of the potential patients for OCA have few options besides total joint 
replacement. This type of procedure improves pain and mobility but is not appropriate for 
a young and active individual. There is also the concern of implant wear, osteolysis, and 
peri-prosthetic failure.
20,21
  
Osteochondral allografts (OCAs) have gradually increased in popularity among 
orthopedic surgeons because they are the only option for treatment of articular cartilage 
lesions that replaces damaged tissue in a biologically appropriate manner. The defect is 
filled with hyaline cartilage instead of hyaline-like or fibrocartilage. It has also been 
demonstrated that chondrocytes in the OCA are viable after implantation in the patient.
22-
25
  
History 
OCAs have been used for treatment of articular cartilage pathology for more than 
a century. Lexer was the first to use OCA in 1908 and had a reported a success rate of 
4 
 
approximately 50%.
26
 However, difficulties associated with technical aspects of the 
surgery, among other issues, contributed to the discontinuation of the procedure. Tumor 
surgeons then began using the technique again in the 1970s. Despite early successes 
during the resurrection of this procedure, it was not used widely because of the limiting 
factor of tissue availability.
27
 Until 1998 when OCA became commercially available 
from several tissue banks, the use of fresh OCA in North America was restricted to two 
institutions which maintained their own systems for retrieving, processing, and storing 
tissues for their own clinical use.
28-30
 This review will focus on small fragment OCA for 
articular cartilage pathology in which minimal bone is left on the allograft speed 
integration and avoid other issues with transplanting bone. Larger OCAs with ancillary 
bone used to replace hemijoints or entire condyles in oncologic or massive trauma cases 
are not the focus of this review.  
Indications 
Injuries that involve both cartilage matrix and chondrocytes have an inferior 
repair response that does not regenerate normal hyaline cartilage.
31
 OCA is a technique 
that is indicated for treating articular cartilage defects of full-thickness and greater than 1 
cm
2
.
32,33
 Conditions that can cause lesions or defects of this nature include trauma, 
ostechondritis dissecans (OCD), avascular necrosis, and focal degenerative disease. OCA 
is most commonly used in the knee, but indications for use in the ankle, hip, elbow, and 
shoulder are being investigated. There has also been success using OCA to salvage 
previously failed procedures such as microfracture, autologous chondrocyte implantation, 
and osteochondral autograft transfer.
34
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Contraindications 
Conversely, there are some important considerations before implementing OCA. 
Advanced multicompartmental arthrosis at any age or activity level is currently a relative 
contraindication for OCA. Uncorrected meniscal or ligament pathology and axial 
malalignment of the lower limb also appear to be contraindications for OCA of the 
knee.
34
 Inflammatory diseases such as rheumatoid arthritis and corticosteroid induced 
osteonecrosis are also contraindications for performing OCA.
35
 However there has been 
recent success in repairing OC defects due to steroid induced osteonecrosis.
36
 
Success with OCA 
The use of OCAs to treat articular cartilage defects is an alluring approach due to 
structural integrity, native tissue composition and architecture, and capabilities for 
integration. The bone portion of the graft will incorporate with host bone via creeping 
substitution and the articular cartilage can maintain a functional level of viability by 
receiving adequate nutrition via diffusion of synovial fluid. Importantly, the avascular 
nature of articular cartilage in conjunction with its dense, specialized extracellular matrix 
surrounding the chondrocytes allow this tissue to be transplanted without 
immunosuppression of the patient. Based on best current knowledge, functional survival 
of OCAs after transplantation primarily depends on chondrocyte viability and mechanical 
properties of the graft at the time of implantation into the patient.  Incorporation of the 
graft bone into host bone and preservation of cartilage viability must then be maintained 
for long term success.  
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Incorporation of the osseous portion of the OCA functions to anchor the graft in 
place. The osseous portion of small grafts in replaced by host bone in a process called 
creeping substitution.
37
 Larger grafts, such as replacement of an entire condyle, are 
reinforced but not replaced by host bone.
38
 Osteocytes typically do not survive storage 
without surgical revascularization, which decreases the immunogenicity of the OCA.
39
 In 
an animal model study, Glenn et al. reported that 89% of canine OCAs had full 
incorporation of bony trabeculae into surrounding native bone at three and six months 
post-implantation.
40
 It has also been shown that the bone-to-cartilage ratio does not 
influence the quality of the graft.
41
 
OCAs have been reported to survive at least twenty five years with a stable, 
integrated osseous base, viable donor chondrocytes, and preservation of functional 
extracellular matrix. 
25
 Jamali et al. published a case report in which donor cells from a 
fresh OCA survived for twenty-nine years after OCA procedure.
24
 Also, biopsies from 
fresh OCAs up to 6 years post-transplantation have shown RNA synthesis and 
proteoglycan (PG) production.
22
 
One concern among surgeons and researchers is the effect storage has on the 
OCA in vivo. This was especially true during the advent of FDA-required mandatory 
disease testing when tissue banks were forced to hold OCA for an average of 14 days.
42
 
Previous outcome studies with positive results had all been done involving fresh OCA 
transplanted within a week of donor death and historically within days of excision.
22
 
Subsequent studies have shown positive results with prolonged fresh stored OCA for 20 
days.
43
 Historically, fresh OCAs were typically harvested, stored at 4°C in Ringer’s 
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lactate, and implanted within 24 hours of donor death. Now, OCAs are still considered 
fresh after 28 days of storage at 4°C while awaiting final disease testing. 
Immune response 
Currently, OCA are not HLA defined or blood-type matched before 
transplantation from donor to recipient.
34
 Isolated chondrocytes will elicit an immune 
response, however, the extracellular matrix of intact hyaline cartilage effectively “ hides” 
chondrocytes from the host immune system.
44
 Therefore, intact hyaline cartilage is a 
relatively immunologically privileged tissue and the host does not become sensitized to 
the allograft.
45
 Fresh OCAs takes advantage of this property of the tissue by transplanting 
viable chondrocytes inside an intact extracellular matrix. However, bone and marrow 
components are not immunologically privileged. Prior to transplantation steps are taken 
to minimize bone volume, and grafts are lavaged to remove any leftover marrow 
components.
46,47
 The response is also limited because very few osteocytes are able to 
survive without vascularization, effectively reducing the immune response.
39
 Further, 
osteocytes have been shown to be less resistant to preservation at 37°C.48 The immune 
system accommodates OCAs because of the lack of viable osteocytes after storage and an 
intact extracellular matrix. Graft size plays a role in immune response, as larger grafts 
tend to have a stronger immune response .
49
 Small fragment OCAs with minimal bone, 
therefore, minimize the immunogenic load. Among storage methods, frozen OCAs elicit 
less immune response than fresh OCA yet this response is not necessarily rejection, but 
rather an accommodation of the tissue.
47
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Retrieval studies in humans have consistently shown that patients tolerate the 
OCA immunologically, despite no HLA or blood type matching, and show no histologic 
evidence of rejection.
37,50
 However, a study using MRI found that those patients with 
anti-HLA antibodies had a poorer graft-host interface than those people without anti-
HLA antibodies
45
 Despite the evidence of immune response to OCAs, the clinical 
relevance is unknown. 
47,51
 When taking into account the relative success OCA 
procedures have had in the past, it seems that the immune responds with accommodation 
of the tissue. Importantly, when examining failed OCAs there was no evidence of an 
immune response to the allograft tissue.
37,50,52
 One would assume that if the immune 
system is rejecting these tissues, a response would be especially evident in failures. 
Modulation of the variable immune response seen in OCA may prove to be efficacious in 
the future, however, there needs to be more knowledge and research to determine the 
effects of the immune system on this allograft tissue. OCAs generally always tolerate 
transplantation immunologically, and the use of small-fragment OCA minimizes the host 
response to donor tissue. 
Current tissue bank storage 
The American Association of Tissue Banks establishes guidelines for 
procurement and processing of allograft tissue. All tissue bank facilities are required by 
law to register with the FDA which allows for federal oversight and inspection.
53
 Also, 
accredited tissue banks should be following Current Good Tissue Practice set up by the 
FDA. Recently tissue banks began withholding allograft tissues from surgeons for 14 
days to allow for complete disease testing before releasing tissue for 
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transplantation.
34,43,54
 OCAs are harvested within 24 hours of donor death and aseptic 
techniques are used during the entire process from donor to patient. Acceptable donors 
are between the ages of 15 to 40 years old with articular surfaces that pass a visual 
inspection for quality.
42
 
Detailed medical, social, and sexual histories of potential donors are acquired 
prior to transplantation.
55
 As of August 2007, donors are screened for HIV type 1 and 2 
antibody, hepatitis B surface antigen, total antibody to hepatitis B core antigen (IgG and 
IgM), HTLV-I/HTLV-II antibody, hepatitis C antibody, and a syphilis assay. Also, 
nucleic acid-amplification tests (NATs) are required for HCV and HIV-1. The window 
period, (i.e. time between infection and detection of virus by the screening tests), is seven 
days for the NATs, therefore seven days is the minimum time for withholding the 
allograft. Bacterial cultures are also obtained, and tissue is discarded if there is a positive 
culture for Clostridium or Streptococcus Group. 
53
 Before the newest testing protocol, 
OCA were sometimes held as long as 40 days after harvest. 
After the Ball et al. landmark article in 2004 demonstrating the superiority of 
tissue culture media over lactated Ringer’s, tissue banks began storing OCAs in tissue 
culture medium.
52,56
 Storage in Lactated Ringer’s solution at 4°C was standard practice 
prior to this article. The critical time point for graft implantation is 28 days, after this time 
point cell viability in the prolonged fresh stored OCA begins to fall below 70%.
57
 
Unfortunately because of the current time constraints for transplantation of tissue and 
stringent testing guidelines, large amounts of donor tissue are discarded.
58
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 Storage  
Preservation 
Method 
Tissue Viability Immune Response 
Frozen None ↓↓ 
Cryopreserved ~21%, limited to superficial 
layer 
↓ 
Lactated Ringer’s 60-90% after 7 days ↑ 
Tissue Culture 
Media 4°C 
27-83% after 28 days ↑ 
Tissue Culture 
Media 37°C 
~60% after 28 days Unknown 
Table 1: Comparison of OCA storage methods 
The goal of a storage media for OCA is to maximize chondrocyte viability and 
maintain tissue properties until the tissue can be transplanted. The maintenance of 
chondrocyte viability is important for successful clinical outcome. Malinin and 
colleagues demonstrated that OCAs transplanted after 21 days of storage had more 
degenerative changes after 6 weeks in vivo than the OCAs transplanted before 21 days of 
storage.
59
 
Freezing is commonly used as a preservation method for bulk allograft procedures 
such as oncologic or major trauma cases where it is necessary to have tissues available 
for emergencies.
7
 The method of storing OCAs by freezing the grafts at -80°C kills 
nearly all viable osteocytes and chondrocytes during the freezing process.
39,60-64
 This 
method of storage is not promising for small fragment OCAs that rely on high 
chondrocyte viability for successful outcomes. In the past, freezing OCAs seemed like an 
attractive approach because it could extend the storage period and potentially increase 
availability. In practice, however, freezing OCAs is complicated by the formation of ice 
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that destroys chondrocytes.
65
 The high water content of articular cartilage negatively 
affects chondrocyte survival during the freezing process because of this ice formation. 
It is not surprising the other properties of the tissue would be affected by the lack 
of viable chondrocytes after freezing. Chondrocytes are responsible for the maintenance 
of the extracellular matrix in articular cartilage and the cartilage matrix begins to 
breakdown in the absence of viable chondrocytes. The biomechanical properties of deep 
frozen OCA are inferior to fresh OCA.
66
 Acosta et al. found increased levels of matrix 
metalloproteinases (MMPs) in frozen allografts indicating active degradation of the 
extracellular matrix.
67
 One beneficial effect of storage at -80°C is the decreased 
immunogenicity of the graft.
39
 Frozen allografts are still attractive outside of oncology 
because they allow for more flexibility in scheduling and grants more time for thorough 
disease testing.  
The addition of cryopreservative agents, such as ethylene glycol, glycerol, or 
dimethyl sulfoxide (DMSO), allows the grafts to maintain higher chrondrocyte viability 
than freezing alone. Hypothetically, these supplements should help prevent ice formation 
during the freezing process, therefore, increase viability. It has been shown that frozen 
OCAs where no ice is formed will have good cell recovery after re-warming.
68
 The 
addition of glycerol and DMSO increased chondrocyte viability when compared to 
freezing without cryopreservative agents but the surviving chondrocytes are typically 
isolated in the superficial layer. 
62,64
 Ohlendorf et al. demonstrated that even with survival 
of chondrocytes in the superficial layer there is no survival in the middle or deep layers of 
articular cartilage.
65
 This is likely due to the inability of the  cryopreservative agents to 
penetrate articular cartilage. Full penetration of DMSO and glycerol into articular 
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cartilage requires longer than one hour but letting tissue absorb the cryopreservative 
agents for longer periods of time increases the risk of toxicity.
69,70
 Research continues in 
this area because of the ability to increase schedule flexibility and allow for thorough 
disease testing. 
Malinin et al. cryopreserved allografts with glycerol and then froze them for at 
least 24 hours. The six cryopreserved OCAs were then transplanted into canine knees and 
examined at a later date. The cartilage appeared normal macroscopically but there was a 
loss of chondrocyte nuclei microscopically 4 months after transplantation. Encouraging 
data from this study was the complete healing of bone after 4 months and the absence of 
a chronic inflammatory reaction.
71
 Csonge and colleaugues were able to maintain 
chondrocyte viability of 21.6% after cryopreservation of articular cartilage.
72
 
By the end of the 20
th
 century, fresh cold-stored OCA became available 
commercially, greatly increasing the availability of tissue.
34
 Prior to this, the use of fresh 
OCA was limited to two institutions in North America.
30
 Fresh OCAs have shown the 
best outcomes because of high chondrocyte viability and superior material properties 
maintained during storage. Traditionally, fresh OCAs were transplanted very soon after 
donor death. Until the FDA started requiring disease testing, it was standard practice to 
store at 4°C in Lactated Ringer’s solution and transplant within forty-eight hours.73 
Sammarco et al. demonstrated that OCA stored with this method had close to 100% 
chondrocyte viability at the time of transplantation.
74
 However, tissue banks started 
holding OCAs for a minimum of 14 days to allow for adequate viral and bacterial disease 
testing as mandated by the FDA. Subsequently, surgical transplantation was delayed by 3 
to 6 weeks after initial tissue recovery.
42
 This prolonged fresh storage led to a subsequent 
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decrease in cell viability among other tissue properties. There was concern for some time 
because no long term studies had been done to show the effect prolonged storage had on 
the OCA in vivo. There have since been prospective studies looking at prolonged fresh 
stored allografts that showed success.
43,52,54,58,75
 Unfortunately, laboratory studies have 
shown that allograft quality decreases with increased storage time.
56,76,77
 Improvements 
must be made in tissue culture technique and media constituents to maintain OCAs as 
similar to in vivo tissue after storage as possible. Currently, maintenance of chondrocyte 
viability near 70% until transplantation is the major goal of OCA storage. Studies have 
shown the ability of storage media to maintain this amount of viability for 28 days.
30,56,77
 
Therefore, it is the current goal to utilize fresh stored OCAs within 30 days.
43,75
 
Fetal bovine serum (FBS), a common supplement to tissue culture media included 
proteins with growth factors, hormones, amino acids, sugars and lipids. The addition of 
FBS to storage media at 4°C has been shown to significantly improve chondrocyte 
viability in certain preparations. Allografts stored in media with FBS maintained a 
chondrocyte viability of 67% while the serum-free media maintained only 27.3% of 
chondrocytes after 28 days of storage.
78
 Another study involving the storage of sheep 
knees at 4°C in tissue culture media with FBS evaluated cell viability over the course of 
60 days. Chondrocyte viability was 98% at Day 8, 81% at Day 29, and 52% at Day 60.
30
 
Storage of canine OCAs in culture media with FBS held at 4°C was shown to maintain 
cell viability ~95% of fresh levels up to 14 days. However, cell viability was also shown 
to decrease thereafter to 65-90% at Day 28.
57
 Similarly Malinin et al. demonstrated a 
chondrocyte viability of nearly 100% at 7 days, ~70% at 14 days, and less than 40% after 
21 days in the storage of human OCA.
59
 Pearsall et al. examined chondrocyte viability in 
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refrigerated OCAs stored in culture media and supplemented with FBS at the time of 
transplantation. The average length of storage was 30 days and average chondrocyte 
viability at the time of transplantation was 67%.
76
  
FBS has shown positive results in maintaining tissue properties and chondrocyte 
viability of OCA during storage. Proteoglycan synthesis, measured by 
35
SO4 uptake, of 
human OCA stored in media supplemented with FBS at 4°C was maintained at levels of 
fresh control after 28 days of storage. OCAs stored in serum-free media had a significant 
decrease in proteoglycan synthesis.
78
 Storage at 4°C in DMEM with supplemental FBS 
was also shown to maintain histologic characteristics and a biomechanical properties of 
fresh control canine OCA for 28 days.
79
 Wayne et al. found that GAG content, 
proteoglycan content and histologic appearance did not deteriorate over a period of 60 
days when stored at 4°C in tissue culture media supplemented with FBS.
80
 Amiel et al. 
determined that type II collagen and glycosaminoglycan (GAG) were synthesized and 
maintained at Day 0 levels in canine OCA for 28 days after storage at 4°C.
81
 However, it 
has been shown that s-GAG content per dry weight decreased from 34% on Day 1 to 21% 
on Day 60 in OCAs stored in tissue culture media supplemented with FBS at 4°C.
30
 
Other studies involving the storage of OCA in media supplemented with FBS 
have shown mixed results. Storage of canine OCA showed a significant decrease in 
proteoglycan synthesis after 28 days of storage even with FBS supplementation.
57
 In 
another study examining storage at 4°C, the addition of FBS to tissue culture medium did 
not seem to have much effect on the GAG content of OCAs stored for 28 days.
78
 An early 
study evaluating articular cartilage after storage at 4°C in media supplemented with FBS 
and antibiotics showed a significant decline in GAG content from fresh controls after 5 
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days of storage.
82
 These studies highlight some of the benefits of supplementation with 
FBS to storage media. 
In addition, it is important to evaluate the effect that storage has on OCAs in vivo. 
Oates et al. showed that canine OCA stored for 14 days in DMEM supplemented with 
FBS at 4°C maintained their biochemical and biomechanical composition in vivo just as 
well as the grafts that were implanted fresh.
83
 
 There has been a trend to move away from the use of FBS because of variability 
in its contents, possibility of disease transmission, and possible immunogenic reaction. 
Iatrogenic transmission of Creutzfeldt-Jakob disease has occurred through other 
procedures. Though there are no reports to date of Creutzfeldt-Jakob disease transmission 
through infected bovine serum, the risk remains.
84,85
 Despite the positive effects of FBS 
media supplementation, the risks outweigh the benefits of using this storage supplement 
and there has been a subsequent movement away from this supplement, especially in 
humans. Therefore, there is a need to find a serum-free chemically-defined media that 
will maintain OCA in a manner similar to FBS.  
Serum-free preparations have shown promise in OCA storage especially with a 
chemically defined supplementation to improve tissue viability and material properties. 
Tissue banks have since changed their storage protocol from Lactated Ringer’s solution 
to tissue culture medium, following the work done by Ball and coworkers.
56
 OCAs stored 
in tissue culture media maintained a higher percent of viable chondrocytes when 
compared to those stored in Lactated Ringer’s solution. They demonstrated that human 
OCA plugs stored for 28 days at 4°C in a serum-free culture media maintained 
chondrocyte viability at nearly 85% whereas Lactated Ringer’s solution struggled to 
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maintain 30% chondrocyte viability over the same time period.
56
 Teng et al. confirmed 
these findings by showing that juvenile bovine OCA stored in culture media only 
containing DMEM has significantly higher cell viability after 2 weeks than Lactated 
Ringer’s solution.86 Human femoral condyle OCAs were stored in serum-free culture 
medium at 4°C. Chondrocyte viability was 98% at Day 14 and maintained at 70% on Day 
28.
77
 Allen, et al. examined human OCAs at the time of surgical implantation after an 
average storage time of 20 days and found 80% viability after storage in serum free 
culture media at 4°C.
87
 
Tissue culture media maintains the biochemical and biomechanical properties of 
OCAs better than those stored in Lactated Ringer’s solution. In the past serum free media 
did not seem very promising, a study evaluating porcine OCA found significant 
deterioration of histologic characteristics and proteoglycan synthesis after 7 days.
88
 Since 
this article there have been other publications supporting the maintenance of tissue 
properties in serum-free culture media with the addition of supplements to the media. 
Proteoglycan synthesis was significantly better in OCAs stored in tissue culture media 
supplemented with ascorbic acid and glutamine when compared to those stored in 
Lactated Ringer’s.56 Cartilage matrix properties, GAG content and biomechanical 
parameters, were maintained at levels of fresh controls in human OCAs stored for 28 
days in serum-free culture media at 4°C.
77
 Allen et al. further confirmed the maintenance 
of extracellular matrix and other tissue properties during storage at 4°C in tissue culture 
media for an average of 20 days when they showed that GAG content and indentation 
stiffness was maintained at fresh levels.
87
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Table 2: Comparison of storage media preparations in literature 
 
 
Continuous modifications of the storage medium used for preserving OCA have 
occurred. Robertson et al. found that pro-apoptotic genes were upregulated during storage 
at 4°C that coincided with decreases in chondrocyte viability and proteoglycan 
synthesis.
89
 Since this article, supplementation with apoptosis inhibitors has been an 
active area of research in the storage of OCA. Teng et al. used the apoptosis inhibitor 
Author Preservation 
Method 
% Viability  
(Day 7) 
% Viability 
(Day 14) 
% Viability 
(Day 21) 
% Viability 
(Day 28) 
Allen* DMEM 4°C - - 82% - 
Ball Lactated 
Ringer’s 4°C 
91 80 - 29 
 DMEM 4°C - 91 - 83 
Linn DMEM+FBS 
4°C 
- - - 61 
 DMEM+FBS+
etanercept 4°C 
- - - 68 
Pallante DMEM+FBS  
4°C 
- 85 - 40 
 DMEM 37°C - - - 60 
Pennock DMEM+FBS 
4°C 
   68 
 DMEM 4°C    27 
Teng Lactated 
Ringer’s 4°C 
58 20 - - 
 DMEM 4°C 67 55 31 15 
 DMEM+FBS 
4°C 
94 86 84 45 
 DMEM+IGF-1 70 59 56 5.9 
 DMEM+ZVA
D-fmk 
73 63 52 16.1 
Williams, J DMEM+FBS 
4°C 
- 94-98 75-98 65-90 
Williams, R** DMEM+FBS 
4°C 
98 80  81 
Williams, S. DMEM 4°C 98 97 - 70 
*Day 20 
**Days 8,15,29 
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ZVAD-fmk as a supplement to DMEM. The supplemented media had significantly 
higher cell viability than DMEM alone at week 3; however, it was unable to maintain a 
significantly higher cell viability than DMEM alone at week 4.
86
 Etanercept, a cytokine 
inhibitor, increased chondrocyte viability in the superficial layer and decreased the 
expression of TNF-α when used as a supplement to tissue culture media.90 Bae et al. 
examined the effects that the addition of epigallocatechin-3-O-Gallate (EGCG) had on 
rabbit OCA stored at 4°C. Those grafts stored in media supplemented with EGCG 
maintained cell viability and GAG content better than the media without EGCG.
91
 Nitric 
oxide synthesis was elevated during storage and had a detrimental effect on proteoglycan 
synthesis.
92
 Inhibition of nitric oxide synthesis using a supplementation to tissue culture 
media is another area to be explored. 
Recently, research has explored the possibility of storing OCAs at 37°C. Similar 
to the resurrection of OCAs in the 1970’s, tissue culture techniques are being 
experimented with again. Pallante et al. found higher cell viability after 28 days in the 
articular cartilage from OCA stored at 37°C compared to 4°C. There was only a modest 
decrease in cell viability between the fresh control and grafts stored at 37°C. Storage at 
37°C maintained cartilage thickness, GAG content, and collagen content compared to 
fresh controls after 28 days of storage.
93
 Bian et al. found that culturing bovine OCA at 
37°C in a serum-free medium could actually increase stiffness, as measured by the 
equilibrium modulus, and GAG content. This media was also supplemented with 
dexamethasone.
94
 Another study demonstrated that OCA could maintain chondrocyte 
viability at Day 0 levels for up to 28 days when stored at 37°C with DMEM+, FBS, and 
cycloheximide. Unfortunately, sulfated GAG content decreased significantly from Day 0 
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levels.
95
 Bastian et al. compared chondrocyte and osteocyte viability in tissue stored at 
37°C. They found few live cells in bone, a beneficial effect that would decrease the 
immune response initiated during transplantation, and viable chondrocytes in the 
cartilage layer.
48
 
Retrieval studies 
Author Storage  Diagnosis No. of Knees Avg. time to 
failure (years) 
Gross 4°C Trauma 6 
11 
24 
<1  
2.9  
12  
Kandel  OA,ON, OCD 44 1-7 
Oakeshott 4°C OA, ON 18 2.9 
Williams 4°C Multiple 14 3.5 
Table 3: Selected retrieval studies from literature 
Gross et al. inspected 41fresh OCA used in the repair of posttraumatic defects. 
These OCAs were transplanted to the patient within 72 hours post-harvest. In the 
meantime they were stored in Ringer’s lactate at 4°C. Failures were classified into three 
groups: early, mid-term, and long-term retrievals. Early failures were due to decreased 
chondrocyte viability and nonfunctional ECM whereas later failures were due to fracture 
or incomplete remodeling. Long term survival of OCAs was associated with viable 
chondrocytes, ECM preservation, and graft bone replaced by host bone.
25
 Williams et al. 
examined articular cartilage from failed OCA. These retrieved grafts had been stored at 
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4°C in Lactated Ringer’s solution and transplanted within 5 days of donor death. 
Chondrocyte viability was maintained at above 80% in the transplanted tissue after an 
average 3.5 years in the patient. Metabolic activity and cartilage integrity was also 
sustained from the time of transplantation to retrieval.
52
 The orthopedic transplant 
program began in 1972 at Mount Sinai Hospital in Toronto. One hundred eight patients 
had fresh small-fragment OCAs transplanted in their knees. Twenty-two of these failed; 
however, data is only available for 18 of these patients. Available failures were examined 
histologically, and viable donor chondrocytes and cartilage matrix were seen up to nine 
years post-transplantation.
37
 Kandel et al. examined 22 patients whose OCA had failed. A 
total of 44 OCAs were evaluated at the time of failure. These OCAs were harvested from 
the donor and transplanted to the patient within 24 hours of donor death. Procedures were 
as follows: seven tibial plateau grafts, three femoral condyle grafts, 13 bipolar grafts, and 
two bipolar bicompartmental grafts. Viable chondrocytes were seen up to 7 years post-
transplantation. Also, viable donor chondrocytes were seen in the retrieved OCAs 7 years 
post-transplantation.
50
   
Importantly there was no evidence of an immune reaction to the OCAs evaluated 
in these retrieval studies, further indicating that this is an immunologically privileged 
tissue.  
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Clinical Outcomes 
Author Storage 
Medium 
Time from 
harvest to 
transplantation 
(days) 
Number 
of Cases 
Follow-
Up 
(years) 
Outcomes 5 year 
survival 
 
Aubin 4°C in Lactated 
Ringers 
2 60 10 85% 
survival 
95% 
Chu 4°C in Lactated 
Ringers 
2-6 43 6.2 93% 
survival 
 
Davidson 4°C in tissue 
culture media 
36 10 3.3 100% 
survival 
 
Garrett 4°C in tissue 
culture media 
4 17 3.5 94% 
survival 
 
Ghazavi 
 
4°C in Lactated 
Ringers 
 126 7.5 86% 
survival 
95% 
Gortz 
 
4°C in tissue 
culture media 
5-21 28 5.6 89% 
survival 
 
Gross 
 
4°C in Lactated 
Ringer’s 
3 60 10 80% 
survival 
95% 
LaPrade 
 
4°C in tissue 
culture medium 
20.3 23 3 100% 
survival 
 
McCulloch 4°C in Lactated 
Ringer’s 
24 25 ~3  96%  
McDermott 
 
4°C in Lactated 
Ringer’s 
1 48 6 75% 
success 
 
Meyers   59 2-10 77% 
success 
 
Williams 4°C in tissue 
culture medium 
30 19 4 100% 
survival 
 
Table 4: Outcome studies after implantation of OCAs 
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There was early success using OCA, even with sub-optimal storage methods. 
McDermott et al. prospectively evaluated the first one hundred OCA procedures 
performed from 1972-1983. These OCAs were stored in Lactated Ringer’s at 4°C up to 
24 hours. Overall, the procedure was mildly successful. The success rate in the trauma 
group was most promising  at 75% success.
35
 Myers and colleagues found a success rate 
of 77% after 2-10 years post-transplantation of osteochondral allografts in 58 patients.
96
 
Recently, McCulloch et al. found success in using OCAs stored in Lactated Ringer’s for 
an average of 24 days. In this prospective study, 25 patients received prolonged fresh 
stored OCAs and showed significant improvement in function after an average follow up 
of 35 months. Only one allograft was reported as a failure and 88% of the OCAs showed 
incorporation of host bone at the time of follow up.
75
 
OCAs were used to correct defects in patients due to osteochondritis dissecans 
(OCD) in 17 patients. Grafts were stored in tissue culture medium at 4°C and 
transplanted to patient within four days of donor death. There was a survival rate of 94% 
after an average three and a half years.
97
 
Fresh stored OCAs have proven to be a viable treatment option in many outcome 
studies. Fresh small-fragment OCAs were used to correct posttraumatic defects in 126 
knees. These grafts were harvested within 24 hours of donor death and stored at 4°C in 
Ringer’s lactate. After an average follow-up of 7.5 years, the OCAs had a success rate of 
86%. Failures were associated with worker’s compensation cases and bipolar grafts.98 
Chu et al. evaluated 43 unipolar OCAs that were stored in Ringers lactate at 4°C and 
transplanted within 2-6 days of donor death. After an average of 6 years, 84% of unipolar 
OCAs were rated good or excellent. Among the 43 OCAs transplanted only one was 
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rated a failure.
99
 Sixty patients were involved in this study evaluating the use of OCAs 
stored in Ringers lactate at 4°C for large posttraumatic defects (>3cm
2
). In these patients, 
84% had excellent or good scores after an average follow up of 10 years.
73
 In another 
example of OCAs having great success in the repair of post-traumatic defects, distal 
femoral osteochondral allografts were stored similarly to the previous two studies above. 
In 60 patients receiving femoral condyle grafts with an average follow up of 10 years, 
80% of these survived.
100
 
In what used to be a contraindication to this procedure, fresh OCAs were used to 
repair 28 knees due to steroid-associated osteonecrosis. The average time to follow up 
was 5.6 years and at this time there was an 89% survival rate. Donor tissue was procured 
within 24 hours of death, stored in tissue culture media at 4°C, and transplanted within 5-
21 days.
36
 
The following studies were important because they confirmed that OCAs were 
still successful in vivo after prolonged fresh storage at 4°C. Nineteen patients whose 
articular cartilage defects were corrected with OCA stored at 4°C in tissue culture 
medium for an average of 30 days were evaluated. The average follow-up period was 4 
years and 100% of the grafts survived. These patients also had increased functional 
scores based on the Activities of Daily Living Scale of the Knee Outcome Survey.
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Davidson and colleagues evaluated eight patients, two of which had bilateral OCA, who 
received femoral condyle OCAs stored for an average of 36 days in serum-free culture 
media at 4°C. A second-look arthroscopy was performed 40 months after transplantation 
and a biopsy was taken from the donor and native cartilage. Cell viability between native 
and donor cartilage was not statistically different. Also on clinical assessment, OCAs 
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improved function.
58
 LaPrade et al. examined patients whose femoral condylar articular 
cartilage defects were treated with OCAs stored at 4°C for an average of 20 days in 
serum-free culture medium. Significant clinical and functional improvements were noted 
after an average follow up of 3 years. The procedure was a success in all of these 
patients.
43 These studies provided the much needed confirmation that prolonged fresh 
stored OCAs were still a viable treatment option. 
 Articular cartilage pathology is a common finding in the orthopedic world and 
current treatments are not sufficient to repair cartilage defects in an appropriate manner. 
OCAs are a promising treatment but improvements need to be made to prolong the fresh 
storage of tissue. Viability decreases rapidly after 28 days and disease testing takes 14 
days on average, this leaves roughly a 14 day window for transplantation of tissue that 
severely hampers scheduling and tissue availability to patients.
42,57
 This thesis will 
examine the effect of OCA storage at 37°C with different media supplementations. 
Tissue will be evaluated at 28 and 56 days for viability, biochemical contents, and 
biomechanical properties. Media will also be evaluated to determine differences in the 
protein release from tissue in different media preparations. 
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CHAPTER 2 
 
 
STUDY 1: OSTEOCHONDRAL ALLOGRAFT PRESERVATION IN A SERUM-
FREE CHEMICALLY DEFINED MEDIA 
 
1. Experimental Purpose and Hypothesis 
Despite the prevalence of articular cartilage pathology, science has struggled with 
finding a treatment to halt the progression to OA. To date, reports exist on the cell 
viability, biochemical, biomechanical, molecular, and histologic properties during the 
storage of OCA, however, there is not one that characterizes all of these properties. It is 
the purpose of this study, therefore, to take a comprehensive look at the effects of a 
Control and Test media at 4°C or 37°C after 28 and 56 days of storage. This study will 
also evaluate the effects of different storage media or temperatures on OCA metabolism 
based on cytokines, chemokines, and inflammatory mediators. We hypothesized that the 
OCA stored at 37°C in the Test media would have better maintenance of cell viability 
and tissue properties than the other storage medias or temperatures.  
2. Materials and Methods 
a. Tissue Harvest and Culture 
Osteochondral allografts (OCAs) were aseptically harvested within four hours of death 
from medial and lateral femoral condyles and tibial plateaus of 10 adult canine cadavers 
euthanized for reasons unrelated to this study. Allografts were stored overnight in 
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Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented 
with 1X insulin-transferrin-selenium (ITS, BD Biosciences, San Jose, CA), 1X penicillin-
streptomycin-Fungizone™ (PSF), L-Glutamine, 0.9mM Sodium Pyruvate, 50µg/mL L-
ascorbic acid, and MEM Non-Essential amino acids (Invitrogen, Carlsbad, CA) at 37°C, 
95% humidity, and 5% CO2. Day 0 Control OCA were aseptically harvested from one 
femoral condyle and tibial plateau of 5 adult canine cadavers euthanized for reasons 
unrelated to this study. These OCAs were stored overnight in the media described 
previously and evaluated the following day. 
The volume of each OCA (n=40) was measured and multiplied by 25-30 times that 
amount to determine the volume of media for each allograft. The OCA were cultured in a 
Control media (DMEM supplemented with ITS 0.9mM Sodium Pyruvate, 50µg/mL L-
ascorbic acid, and MEM Non-essential amino acids) or in the Test media (DMEM 
supplemented with 1X insulin-transferrin-selenium-bovine serum albumin-linoleic acid 
[ITS+, BD Biosciences, San Jose, CA], 0.9mM Sodium Pyruvate, 50µg/mL L-ascorbic 
acid, MEM Non-Essential amino acids, 10.0µM dexamethasone sodium phosphate [APP 
Pharmaceuticals, Schaumburg, IL], 250 µg/mL sodium tetraborate [Sigma Aldrich, St. 
Louis, MO], and 2.5 ng/mL rhTGF-β3 [R&D Systems, Minneapolis, MN]). 
Once the OCAs were aseptically processed they were preserved in either Control 
media or Test media at 4°C or 37°C for 28 or 56 days. Each stored specimen had its own 
contralateral control on the opposite leg. The media were changed every 7 days and 
media samples were saved for later analysis. At each time point full-thickness cartilage 
was evaluated for chondrocyte viability, biochemical analysis, and biomechanical 
analysis. 
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b. Chondrocyte Viability 
Full thickness cartilage from each storage group was used to determine chondrocyte 
viability. Quantititative analysis of chondrocyte viability was determined by manually 
counting live and dead cells from images taken at 10X magnification using an Olympus F 
view II camera and Micro Suite Basic Edition software. CellTracker™ Green CMFDA 
(5-chloromethylfluorescein diacetate, Invitrogen, Carlsbad, CA) was used to visualize 
live cells and ethidium homodimer-1 (EthD-1, Invitrogen, Carlsbad, CA) to visualize 
dead cells. Percent live cells were determined by taking the total number of live cells 
divided by the total amount of cells in the sample.  
c. Glycosaminoglycan (GAG) Assay 
After PBS wash, cartilage plugs were blotted with a paper wipe and weighed on 
balance to obtain the wet weight. Dry weight was determined after lyophilization for 24 
hours. Cartilage tissue was the then digested in 50µL papain solution for 3 hours at 60°C. 
Sulfated-GAG (s-GAG) concentration within the cartilage matrix was determined using 
aliquots of digest solution using the 1,9 dimethylmethylene blue (DMMB) dye-binding 
assay. S-GAG content was determined from the ratio of s-GAG to total tissue dry 
weight
101
 and reported at µg GAG/mg dry weight. 
The DMMB assay was used to determine the amount of s-GAG release into media 
after each week of storage using the samples obtained during weekly media changes. 
Media GAG was reported as µg GAG normalized by multiplying by media volume used 
for storage. 
d. Hydroxyproline (HP) Assay 
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The hydroxyproline (HP) content was determined using a colorimetric assay modified 
to a 96-well format. HP content was used as a measure of total collagen content.
102
 A 50-
µL aliquot of the digest solution was mixed with 50 µL 4N NaOH and the mixture was 
autoclaved for 20 minutes at 121° C to hydrolyze the sample. The sample was then mixed 
with the chloramine T reagent and incubated at 25° C for 25 minutes, followed by mixing 
with Ehrlich aldehyde reagent. The chlorophore was developed at 65° C for 20 minutes. 
The absorbance was then read at 550 nm using a Synergy HT (Bio-TEK, Highland Park, 
VT) and the samples were compared with an HP standard to determine the HP 
concentration of the sample. Results were standardized to tissue dry weight and reported 
as µg HP/mg dry weight. 
e. Nitric Oxide (NO) assay 
Nitrite concentrations were measured spectrophotometrically using the Griess reaction 
(Promega Corp., Madison, WI) as described by the manufacturer. The concentrations 
were used to determine nitric oxide synthesis. A 25µL aliquot of medium diluted with 
25µL of phosphate buffered saline was incubated with 50µL of 0.1% sulfanilamide in 5% 
phosphoric acid, then with 50µL of 0.1% N-1-naphthylethylenediamine dihydrochloride 
for 5 minutes at room temperature. Absorbance was then read at 520nm. Values were 
reported as µg NO/mL and then normalized for each sample by multiplying the 
concentration by amount of media used for storage. 
f. PGE2 assay 
Concentrations of PGE2 in the media samples were quantified by a competitive 
enzyme immunoassay (Cayman Chemical, Ann Arbor, MI). The samples and standards 
were incubated with 50µL of goat polyclonal anti-mouse IgG antibody and 50µL of 
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acetylcholinesterase-linked tracer. The plate was covered with a plastic film and 
incubated for 18 hours at 4°C. Before developing the plate, Ellman’s Reagent was 
reconstituted with UltraPure water. The plate was rinsed with Wash Buffer and Ellman’s 
Reagent was added to the wells. The plate was covered and allowed to develop in 
darkness while on an orbital shaker for 60-90 minutes. The absorbance was measured at a 
wavelength of 410nm. Sample concentrations were determined from the standard curve 
and reported as picogram (pg) per mL as noted in the manufacturer’s directions . PGE2 
was then normalized to media volume by multiplying pg PGE2/mL by the volume of 
media the OCA used for storage. 
g. Cytokine assays 
An aliquot of femoral condyle and tibial plateau storage media from every group at 
Days 7, 28, 56 was thawed. Each aliquot was analyzed using a multiplex canine cytokine 
and chemokine immunoassay (Millipore Corp., Billerica, MA) based on the xMAP 
platform (Qiagen Inc, Valencia, CA)  for GM-CSF, IFN-γ, IL-7, IL-15, IL-2, IP-10, IL-4, 
KC, IL-6, IL-8, IL-10, IL-18, MCP-1, and TNF-α according to the manufacturers’ 
directions. Media samples were mixed with anti-chemokine and cytokine monoclonal 
antibody-charged, small, polystyrene microspheres in a 96 well plate. Following an 
overnight incubation at 4° C, a polyclonal secondary antibody was added and also 
streptavidin-phycoerythrin. The median fluorescence intensity (MFI) was determined for 
each sample and concentration was reported as pg/mL. The values were then normalized 
by multiplying the concentration by the amount of media used to store the OCA. 
Another aliquot of femoral condyle storage media from every group at Days 7, 28, and 56 
was analyzed using a multiplex human matrix metalloproteinase (MMP) immunoassay 
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based on the xMAP platform (Qiagen Inc, Valencia, CA) for 5 MMPs: MMP1, MMP2, 
MMP3, MMP9, MMP13. This assay has been previously shown within our laboratory to 
cross-react with samples of canine origin 
103
. Values were reported as pg cytokine or 
MMP and normalized by multiplying the concentration by the amount of media used to 
store the OCA. 
h. Biomechanical Testing 
At each end point, 4mm plugs were removed from the articular cartilage and 
immediately put in a -80°C freezer until biomechanical testing could be done.
56
 The 
dynamic modulus of cartilage specimens were determined by unconfined compression 
with loading to 10% strain at a rate of 0.05% per second, after an initial 0.02-N tare load 
(elastic modulus, or Eγ). Dynamic modulus (G*) was measured by superimposing 2% 
peak-to-peak sinusoidal strain at 0.1 Hz. Values were reported as milli-Pascals (MPa). 
i. Histologic Assessment 
For histologic evaluation, 2 mm-thick sagittal sections of the OCA were cut and fixed 
in 10% formalin, and then placed in a decalcifier in Surgipath Decalcifier II. After 
decalcification and subsequent routine histologic processing, each specimen was 
embedded in paraffin, and sectioned through the sagittal plane with 5µm thickness. These 
samples were then stained with hematoxylin and eosin (H&E), toluidine blue (T blue), 
and Masson’s trichrome. Each section was subjectively assessed by one investigator. 
Each section was qualitatively assessed for cartilage architecture, GAG content, and 
collagen. 
j. Immunohistochemistry 
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As described before, 2 mm sagittal sections were cut and fixed in 10% formalin. After 
fixation was complete, samples were decalcified in 10% disodium 
ethylenediaminetetraacetic (EDTA) acid. After decalcification and subsequent routine 
histologic processing, each specimen was embedded in paraffin, and sectioned 5 µm 
through the sagittal plane. For immunohistochemical analysis, unstained sections were 
deparaffinized in xylene and rehydrated in graded ethanol solutions. The samples were 
permeabilized with a 0.1% trypsin solution at 36° C for 60 minutes and then blocked with 
a 10% bovine serum albumin at 40° C. Slides were incubated overnight at 4° C in 
predetermined dilutions of the primary antibodies: collagen type II (rabbit polyclonal 
antibody, Abcam, Cambridge, UK) and proteoglycan (mouse anti-human antibody, 
Millipore Corp., Billerica, MA). 
The next day slides were rinsed in Tris-buffered saline before being incubated with the 
secondary antibody. Collagen type II was labeled with goat anti-rabbit fluorescein 
isothiocyanate (FITC, Millipore Corp., Billerica, MA) and proteoglycan was labeled with 
goat anti-mouse rhodamine (Millipore Corp., Billerica, MA). Samples were coverslipped 
and reviewed using fluorescent light microscopy. Negative controls were used as 
comparison in which the primary (but not secondary antibody) was omitted from the 
slides to see if any stain was due to fluorescence aside from the target region. 
Immunohistochemical images were subjectively assessed.  
k. Statistical Analysis 
Statistical analyses were done using the SigmaStat® computer software program (San 
Rafael, CA). Data were pooled for each endpoint, Day 28 and Day 56, and comparisons 
were made between the four storage media and Day 0 controls. A one way ANOVA 
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using Tukey post-hoc comparisons was used for statistical analysis and significance set at 
p<0.05. 
A two-tailed, equal variance T-test was used to determine statistical significance in the 
biomechanical data. Significance was set at p<0.05. 
3. Results 
a. Chondrocyte Viability 
i. Femoral condyle OCAs stored in the 37° C Control media had significantly 
higher cell viability at Day 28 than 4°C Control and 4°C Test ( p=0.016, 
p=0.01). At Day 56, the 37° C Control media had significantly higher cell 
viability than 4°C Control (p=0.008),  4°C Test( p=0.015), and 37°C Test 
(p=0.023).  
 At Day 28, the Day 0 viability was significantly higher than 4°C Control 
(p=0.007) and 4°C Test (p=0.01) media. At Day 56, the Day 0 viability was 
significantly higher than 4°C Control (p=0.032), 4°C Test (p<0.001), and 37°C 
Test (p=0.002).  
ii. Tibial plateau OCAs stored in the 37° C Control media had significantly higher 
cell viability at Day 28 than both 4°C Control (p=0.039) and 4°C Test (p<0.001) 
media. Also, those stored in the 37°C Test media had significantly higher 
viability than OCA stored in the 4°C Test (p=0.019) media. At Day 56, the 
37°C Control media had significantly higher cell viability than 4°C Control 
(p=0.034), 4°C Test (p<0.001), 37°C Test (p=0.015) media.  
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At Day 28, the Day 0 viability was significantly higher than 4°C Control 
(p=0.008), 4°C Test (p=0.008), and 37°C Test (p=0.001) media. At Day 56, the 
Day 0 viability was significantly higher than 4°C Control (p=0.008), 37°C 
Control (p=0.043), 4°C Test (p=0.008), and 37°C Test (p=0.008) media.  
iii. See Tables on p.52. See Figures on pp. 62-67. 
b. Tissue GAG content 
i. Femoral condyle OCAs had no significant differences in tissue GAG content at 
Day 28. At Day 56, The OCAs stored in 37°C Test media had significantly less 
tissue GAG content than 4°C Control (p=0.027) and 37°C Control (p=0.033) 
media.  
At Day 28, there were no significant differences between Day 0 controls. 
However, at Day 56 the Day 0 OCAs had significantly more tissue GAG 
content than those stored in 37°C Test (p=0.003) media. 
ii. At Day 28, tibial plateau OCAs stored in the 4°C Control media had 
significantly higher tissue GAG content than 37°C Control (p=0.008) and 37°C 
Test (p=0.021) media. At Day 56, OCAs stored in the 4°C Control media had 
significantly higher tissue GAG content than 4°C Test (p=0.017) and 37°C Test 
(p=0.003) media. Also at Day 56, the 37°C Control media had significantly 
more tissue GAG content than 37°C Test (p=0.016) media.  
There were no significant differences from Day 0 controls at Day 28. At Day 
56, Day 0 OCAs had significantly higher tissue GAG content than 4°C Test 
(p=0.02) and 37°C Test (p=0.008) media.  
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iii. See Tables on p.53. See Figures on p. 68 
c. Media GAG Content 
i. Femoral condyle OCAs stored in 37°C Test media had significantly more GAG 
release into media than those stored in 37°C Control media at Days 21(p=0.003) 
and 28 ( 0.001). Those stored in the 37°C Test media had significantly more 
GAG release than 4°C Control at Days 7 (p<0.001), 14 (p<0.001), 21 (p<0.001), 
28 (p<0.001), 35 (p=0.016), 42 (p=0.016), 49 (p=0.016), 56 (p=0.016). OCAs 
stored in 37°C Test media had significantly more GAG release than those stored 
in the 4°C Test media at Days 7 (p=0.004), 14 (p=0.001), 21(p<0.001), and 28 
(p=0.001). Those stored at 37°C Control media had significantly more GAG 
release than those stored in the 4°C Test media at Days 7 (p=0.011), 14 
(p=0.025), 28 (p=0.026), 49 (p=0.008), and 56 (p=0.032). OCAs stored in 37°C 
Control media had significantly more GAG release than those stored in 4°C 
Control media at Days 7 (p<0.001), 14 (p<0.001), 21 (p<0.001), 28 (p<0.001), 
35 (p=0.008), 42 (p<0.001), 49 (p<0.001), 56 (p=.008). Lastly, OCAs stored in 
4°C Test media had significantly more GAG release than 4°C Control media on 
Days 7 (p=0.005), 14 (p<0.001), 21 (p<0.001), 28 (p=0.001), 35 (p=0.008), 42 
(p=0.023), 49 (p=0.026), and 56 (p=0.041). 
ii. Tibial plateau OCAs stored in 37°C Test media had significantly more GAG 
release into media than those stored in 37°C Control media at Days 21 
(p=0.001), 28 (p=0.003), and 35 (p=0.045). Those stored in the 37°C Test media 
had significantly more GAG release than 4°C Control at Days 7 (p=0.002), 14 
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(p<0.001), 21 (p<0.001), 28 (p<0.001), 35 (p=0.016), 42 (p=0.008), 49 
(p=0.016), and 56 (p=0.008). OCAs stored in 37°C Test media had significantly 
more GAG release than those stored in the 4°C Test media at Days 7 (p=0.032), 
14 (p<0.001), 21 (p<0.001), 28 (p=0.001), 35 (p=0.016), 49 (p=0.011), and 56 
(p=0.018). Those stored at 37°C Control media had significantly more GAG 
release than those stored in the 4°C Test media at Days 7 (p=0.01), 14 
(p=0.004), 21 (p=0.017), 28 (p=0.003), 49 (p=0.015), and 56 (p=0.024). OCAs 
stored in 37°C Control media had significantly more GAG release than those 
stored in 4°C Control media at Days 7 (p<0.001), 14 (p<0.001), 21(p<0.001),  
28 (p<0.001), 35 (p=0.013), 42 (p=0.008), 49 (p=0.008), and 56 (p=0.002). 
Lastly, OCAs stored in 4°C Test media had significantly more GAG release 
than 4°C Control media on Days 7 (p=0.01), 14 (p=0.01), 21 (p=0.001), 28 
(p=0.001) 
iii. See Tables on p. 54. See Figures on p. 69 
d. Hydroxyproline (HP) content 
i. There were no significant differences between femoral condyle OCA storage 
group’s HP content Day 28 or 56.  
Also, there were no significant differences at any time point from Day 0. 
ii. At Day 28, tibial plateau OCA stored in 37°C Test media had significantly 
higher HP content than 37°C Control (p=0.016). There were no significant 
differences between HP content of tibial plateaus at Day 56.  
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At Day 28, OCAs stored in 37°C Test media had significantly higher HP 
content than Day 0 (p=0.044). At Day 56, OCAs stored in 4°C Test media had 
significantly higher HP content than Day 0 (p=0.046).  
iii. See Tables on p.55. See Figures on p.70 
e. Media NO content 
i. Femoral condyle OCAs stored in 37°C Control media had significantly more 
NO release at Day 7 than 4°C Control (p=0.002) and 4°C Test (p=0.013) media. 
There were no significant differences at Day 28 or 56. 
ii. Tibial plateau OCAs stored in 37°C Control media had significantly more NO 
release at Day 7 than 4°C Control (p=0.001) and 4°C Test (p=0.024) media. 
Also at Day 7, NO release was significantly higher in the OCAs stored in 37°C 
Test media than those stored in 4°C Control media (p=0.01). At Day 28, OCAs 
stored in 37°C Test media continued to have significantly more NO release than 
those stored in 4°C Control media (p=0.004). There were no significant 
differences at Day 56. 
iii. See Tables on p.56. See Figures on p.71 
f. Media PGE2 content 
i. There were no significant differences between femoral condyles at Day 7.  
At Day 28, OCAs stored in the 37°C Control media had significantly more 
PGE2 release than 4°C Control (p=0.02) and 4°C Test (p<0.001) media. Also at 
Day 28, 4°C Control media had significantly more PGE2 release than 4°C Test 
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(p=0.005) media. Finally, the OCAs stored in 37°C Test media had significantly 
more PGE2 release than 4°C Test (p=0.007) media.  
At Day 56, OCAs stored in 37°C Control had significantly more PGE2 release 
than those stored in 4°C Control (p=0.041) and 4°C Test (p=0.023) media.  
ii. At Day 7, there was no significant differences between tibial plateau storage 
groups.  
At Day 28, the OCAs stored in 37°C Test media had significantly more PGE2 
release than those stored in 4°C Control (p<0.001), 37°C Control (p=0.003), and 
4°C Test (p<0.001) media. Also at Day 28, those stored in 37°C Control media 
had significantly more PGE2 release than 4°C Control (p=0.021) and 4°C Test 
(p<0.001) media. Finally, the OCAs stored in 4°C Control media had 
significantly more PGE2 release than 4°C Test (p<0.001) media. 
At Day 56, the OCAs stored in 37°C Control media had significantly more 
PGE2 release than those stored in 4°C Control (p<0.001) and 4°C Test 
(p<0.001) media. 
iii. See Tables on p.56. See Figures on p.72 
g. Media MMP content  
i. MMP-2 release was significantly higher from OCAs stored in the 37°C Test 
media than 4°C Control (p=0.008) and 4°C Test (p=0.008) media on Day 7.  
Also at Day 7, the 37°C Control had significantly higher levels of MMP-2 
release than 4°C Control (p=0.008) and 4°C Test (p=0.008) media.  
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At Day 28, OCAs stored in 37°C Control media had significantly higher levels 
of MMP-2 release than 4°C Control (p=0.008) and 4°C Test (p<0.001) media. 
At Day 56, OCAs stored in 37°C Control media had significantly higher levels 
of MMP-2 release than 4°C Control (p=0.008) and 4°C Test (p=0.008) media. 
ii. MMP-3 release into media was significantly higher from OCAs stored in 37°C 
Control media than those stored at 4°C Control media at Days 7 (p=0.031), 28 
(p=0.048), and 56 (p=0.008).  
The MMP-3 release into media was significantly higher from OCAs stored in 
37°C Control media than those stored in 4°C Test media at Days 28 (p=0.032) 
and 56 (p=0.008). 
iii. MMP-13 release into media was significantly higher from OCAs stored in 37°C 
Control media than 4°C Control at Days 7 (p=0.008), 28 (p=0.008), and 56 
(0.008).  
MMP-13 release into media was significantly higher from OCAs stored in 37°C 
Control media than 4°C Test at Days 7 (p=0.016), 28 (p=0.008), and 56 
(p=0.008).  
Also, on Day 28 the release of MMP-13 into media was significantly higher 
from OCAs stored in 37°C Control media than 37°C Test media (p=0.016). 
iv. See Tables on p. 57. See Figures on p. 73 
h. Media cytokine release  
i. Femoral condyles 
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1. OCAs stored in 37°C Control media had significantly higher release of 
KC than those stored in the 4°C Control media at Days 7 (p=0.011), 28 
(p=0.008), and 56 (p=0.008). Also, OCAs stored in 37°C Control media 
had significantly higher KC release than those stored in 4°C Test media 
at Days 28 (p=0.008) and 56 (p=0.008). 
2. IL-6 release from media was significantly higher from OCAs stored in 
37°C Control media than those stored in 4°C Control media at Day 7 
(p=0.032). No other significant differences were found. 
3. At Day 7, IL-8 levels were significantly higher in 37°C Control media 
than 4°C Control (p=0.01), 4°C Test (p=0.019), and 37°C Test 
(p=0.036) media. Also, the 37°C Test media had significantly higher 
levels of IL-8 than the 4°C Control (p=0.025) media.  
At Day 28, IL-8 release from OCAs into media was significantly higher 
in those stored in the 4°C Test media than 4°C Control (p=0.032) 
media. 
At Day 56, 37°C Control media had significantly higher release of IL-8 
than 4°C Control (p=0.008) and 4°C Test (p=0.008) media. 
4. At Day 7, MCP-1 release from OCA stored in 37°C Control media was 
significantly higher than 4°C Control (p=0.008), 4°C Test (p=0.008), 
and 37°C Test (p=0.008) media. Also on Day 7, release of MCP-1 from 
OCAs stored in 37°C Test media at than those stored in 4°C Control 
(p=0.015) media.  
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At Day 28, MCP-1 release was significantly higher from OCAs stored 
in 37°C Control media than those stored in the 37°C Test media. Also at 
Day 28, release of MCP-1 from OCAs stored in 4°C Test media was 
higher than release from those stored in 37°C Test media. 
At Day 56, MCP-1 release from OCA stored in 37°C Control media 
was significantly higher than 4°C Control (p=0.008), 4°C Test 
(p=0.008), and 37°C Control (p=0.008) media. 
5. See Tables on p. 58. See Figures on p. 74 
ii. Tibial plateaus 
1. At Day 7, release of KC was significantly higher in 37°C Control than 
4°C Control (p=0.001) and 4°C Test (p=0.004) media. Also, 37°C Test 
media had significantly higher release of KC than 4°C Control 
(p=0.007) and 4°C Test (p=0.024) media. 
At Day 28, release of KC was significantly higher in 37°C Control than 
4°C Control (p=0.008) and 4°C Test (p=0.008) media. Also, 37°C Test 
media had significantly higher release of KC than 4°C Control 
(p=0.008) and 4°C Test (p=0.008) media. 
At Day 56, release of KC was significantly higher in 37°C Control than 
4°C Control (p=0.008) and 4°C Test (p=0.008) media. The 37°C Test 
media had significantly higher release of KC than 4°C Control 
(p=0.032). 
2. There were no significant differences in IL-6 release at any time point. 
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3. At Day 7, 37°C Control media stored at had significantly higher levels 
of IL-8 release than 4°C Control (p=0.002), 4°C Test (p=0.002), and 
37°C Test (p=0.016) media. Also at Day 7, the 37°C Test media had 
significantly higher levels than 4°C Test (p=0.032) media.  
At Day 28, the 37°C Test media had significantly higher levels of IL-8 
release than 4°C Control (p=0.008), 4°C Test (p=0.008), and 37°C 
Control (p=0.032) media. Also at Day 28, the 37°C Control media had 
significantly higher levels of IL-8 than 4°C Control (p=0.008) and 4°C 
Test (p=0.008) media.  
At Day 56, the 37°C Control media had significantly higher levels of 
IL-8 release than the 4°C Control (p=0.002) media. 
4. At Day 7, the 37°C Control media had significantly more MCP-1 
release than 4°C Control (p=0.008), 4°C Test (p=0.008), and 37°C Test 
(p=0.013) media. Also at Day 7, the 37°C Test media had significantly 
more MCP-1 release than 4°C Control (p=0.018) and 4°C Test 
(p=0.027) media. 
At Day 28, the 37°C Control media had significantly more MCP-1 
release than 4°C Control (p=0.008), 4°C Test (p=0.008), and 37°C Test 
(p<0.001) media. Also at Day 28, the 37°C Test media had significantly 
more MCP-1 release than 4°C Control (p=0.008) and 4°C Test 
(p=0.008) media. 
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At Day 56, the 37°C Control media had significantly more MCP-1 
release than 4°C Control (p=0.008), 4°C Test (p=0.008), and 37°C Test 
(p<0.001) media. Also at Day 56, the 37°C Test media had significantly 
more MCP-1 release than 4°C Control (0.008) media. 
5. See Tables on p.59. See Figures on p.75. 
i. Biomechanical Analysis 
i. At Day 28, femoral condyle Day 0 Control’s elastic modulus was significantly 
higher than 4°C Control (p=0.003), 37°C Control (p=0.004), and 4°C Test 
(0.002) media. Dynamic modulus of Day 0 Controls was significantly higher at 
Day 28 than full thickness cartilage stored in 37°C Control media. However, at 
Day 56 there were no significant differences between femoral condyle storage 
groups in elastic or dynamic modulus. See Tables on p. 60 and Figure on p.76. 
ii. At Day 28, full thickness cartilage from tibial plateaus elastic modulus of Day 0 
Controls was just barely statistically significantly higher than those stored in 
37°C Control (p=0.049) media. Also, the dynamic modulus from Day 0 controls 
was significantly higher than those stored in 37°C Control (p=0.0017) media at 
Day 28. At Day 56, the dynamic modulus was significantly less in OCAs stored 
in 37°C Control media than 4°C Test (p=0.0278) and 37°C Test (p=0.0363) 
media. See Tables on p.606161 Figure on p.77 
j. Histology  
i. Qualitative light microscopy analysis of femoral condyle OCA histology 
sections. Slight degenerative changes were seen in the architecture in OCAs 
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H&E staining on Day 28. The loss of normal architecture was pronounced as 
well as a loss of cells in the superficial layer on Day 56 of OCAs in the 37°C 
Test media. There was a loss of T-blue staining in the superficial layer of the 
OCAs stored in 37°C Control media at Days 28 and 56 compared to Day 0. Also 
at Day 56, the OCAs in 4°C Test media had less stain in the superficial layer. 
OCAs stored in 37°C Test media had a pronounced loss of T-blue stain at Day 
28 and 56. Trichrome stain was maintained throughout storage. See Figures 
pp.78,80-85 
ii. Qualitative light microscopy analysis of tibial plateau OCA histology sections. 
Slight degenerative changes were seen in OCAs H&E staining on Day 28 and 
56. There was a slight loss of T-blue staining in OCAs stored in 37°C Control, 
4°C Control, and 37°C Test media at Day 28. At Day 56 there was a pronounced 
loss of T-blue staining in OCAs stored in 4°C Test and 37°C Test media 
compared to Day 0 staining. Trichrome stain was maintained throughout 
storage. See Figures on pp.79, 86-91. 
k. Immunohistochemistry 
i. Qualitative light microscopy analysis of femoral condyle and tibial plateau 
immunohistochemistry samples. The samples showed Collagen II throughout all 
layers and proteoglycan was also evident upon examination of all samples. See 
Figures on pp.92-96. 
4. Discussion 
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In this study, the 37°C Control media preserved the tissue better than all other 
storage groups. Similar to the work by Teng and colleagues, the basic media provided 
the best environment for OCA preservation.
86
 This work also confirmed that of 
Pallante et al. that demonstrated a high cell viability by storing OCAs at 37°C.
93
 
However, this study used a serum-free chemically-defined media to achieve this high 
cell viability. 
 4°C Control 37°C Control 4°C Test 37°C Test 
Cell Viability Negative POSITIVE +++ Negative Positive 
ECM Positive Positive Positive Negative 
Biomechanics Positive ++ Positive Positive ++ Positive ++ 
Biomarkers 
Inflammatory 
Cytokines 
MMP’s 
 
Negative 
Negative 
Negative 
 
Positive 
Positive ++ 
Positive ++ 
 
Negative 
Negative 
Negative 
 
Negative 
Negative 
Negative 
Histology Positive Positive Positive Positive 
Table 5: Summary of results from storage of femoral condyle OCAs. 
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 4°C Control 37°C Control 4°C Test 37°C Test 
Cell Viability Negative Positive ++ Negative Positive 
ECM Positive ++ Positive Positive Negative 
Biomechanics Positive ++ Positive Positive ++ Positive ++ 
Biomarkers 
Inflammatory 
Cytokines 
 
Negative 
Negative 
 
Positive ++ 
Positive ++ 
 
Negative 
Negative 
 
Positive 
Positive 
Histology Positive Positive Positive Positive 
Table 6: Summary of results from storage of tibial plateau OCAs. 
Currently, OCAs stored in serum-free media at 4°C maintain GAG content and 
~70% cell viability up to 28 days. However the cell viability in OCAs stored after 28 
days at 4°C is significantly less than Day 0 levels, which is consistent with the OCAs 
stored at 4°C in our study.56,77 The chondrocyte viability of femoral condyle OCAs 
were maintained at Day 0 levels in the 37°C Control media up to 56 days and 
viability was significantly higher in this media than all other groups. The 37°C 
Control media was able to maintain Day 0 levels of viability only to 28 days in tibial 
plateaus, however, it still maintained significantly higher viability than any other 
storage group. It was previously shown that storage of OCAs in media at 37°C could 
maintain high cell viability up to 28 days.
93
 We confirmed these findings and 
improved upon them by maintaining cell viability at Day 0 levels up 56 days. OCA 
storage at 37°C has previously demonstrated the ability to maintain GAG and HP 
content up to 28 days of storage.
93,94
 In this study, tissue glycosaminoglycan (GAG) 
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and hydroxyproline (HP) content of femoral condyles, both measures of extracellular 
matrix quality, were maintained at Day 0 levels in 37°C Control media after 56 days 
of storage. GAG and HP content of tibial plateaus was also maintained at Day 0 
levels in 37°C Control media up to 56 days. The GAG and HP content of OCAs 
stored at 4°C was maintained despite a decrease in cell viability. This would indicate 
a decrease in metabolism. Otherwise, they would have a decrease in GAG or HP 
similar to OCAs that had a decrease in GAG content when stored in 37°C Test media.  
GAG content of media is a measure of GAG release from tissue. The lower tissue 
GAG content of OCAs stored in 37°C Test media corresponded with significantly 
higher levels of media GAG release than the 4°C groups and the 37°C Control, we 
hypothesize that this is due to stress or lack of extracellular matrix maintenance by 
chondrocytes from OCAs stored in the 37°C Test media. The 37°C Control media 
maintained tissue GAG but had significantly more media GAG release than OCAs 
stored at 4°C, this is likely similar to normal metabolism. The low levels of media 
GAG release in OCAs stored at 4°C could be because the cells have entered a 
quiescent state. These general trends were seen in both femoral condyle and tibial 
plateau OCAs. The release of GAG into media could be from the production of 
smaller GAG molecules or catabolic release from tissues. The low amounts of GAG 
release into media from OCAs stored at 4°C support the earlier hypothesis of 
decreased metabolism in these tissues. 
Previous work has shown that NO release into media has a detrimental effect on 
proteoglycan synthesis of OCAs.
92
 The NO release was elevated at Day 7 from 
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femoral condyle OCAs stored in 37°C Control compared to those stored at 4°C. A 
similar trend was seen in tibial plateau OCA. The upregulation in media NO release 
compared to 4°C groups was likely due to surgical insult during the removal of these 
OCAs rather than storage dynamics. On the other hand, PGE2 release showed a time 
dependent increase in release from femoral condyles and tibial plateaus OCAs. At 
Day 7 there were no significant differences between storage groups of femoral 
condyles and tibial plateaus. However, at Day 28 and 56 the femoral condyle OCAs 
stored in 37°C Control media had significantly more PGE2 release into media than 
both 4°C Control and 4°C Test media. Among tibial plateau OCAs at Day 28, those 
stored in 37°C Test media had significantly higher PGE2 release than any other group 
and the 37°C Control media had significantly higher PGE2 release than tibial plateau 
OCAs stored in 4°C Control and 4°C Test media. Surprisingly, at Day 56 the only 
significant differences between tibial plateau OCA storage groups was a significantly 
higher release from those stored in 37°C Control than 4°C Control or 4°C Test media. 
The correlation between tissue viability and increased PGE2 release from OCAs 
stored in 37°C Control media indicate that this could be a marker for tissue viability. 
Also, it is logical that there would be less PGE2 release from OCAs stored in the Test 
media because it is supplemented with dexamethasone, a potent corticosteroid. 
High levels of MMP-2, 3, and 13 continued to be released from femoral condyle 
OCAs stored in 37°C Control media throughout the course of this study. This media 
also maintained chondrocyte viability at Day 0 levels, therefore, these MMPs could 
be markers for tissue viability during preservation. 
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The cytokines KC, IL-8, and MCP-1 remained elevated throughout this study in 
37°C Control media, indicating that they could be markers of tissue viability because 
of the high chondrocyte viability maintained in this media. IL-6 was only elevated on 
Day 7 and this elevation was likely due to inflammation during surgical removal. 
Similar trends in cytokine elevation were seen during both femoral condyle and tibial 
plateau OCA storage. Biomarker research is being continued in our lab, the 
measurement of proteins released in to media could allow tissue banks to assess OCA 
quality without insulting the tissue. This is important because currently there is no 
way to individually assess the quality of OCAs during storage, with biomarkers it 
may be possible to determine the quality of each individual OCA.  
The lesser amount of NO, PGE2, MMP’s, and cytokines from OCAs stored in 
media at 4°C further support the hypothesis that OCAs have a decreased metabolism 
at 4°C. Whether or not this is similar to in vivo metabolism is yet to be determined. 
At Day 28, the elastic and dynamic moduli of full thickness cartilage from 
femoral condyle and tibial plateau OCAs stored in 37°C Control media was unable to 
maintain the stiffness of Day 0. However, at Day 56 these values were not statistically 
significant. These results are confounding and could be due to group differences or 
errors in testing. However, there has been a correlation seen with maintenance of 
biomechanical properties using dexamethasone as a supplement to media. This is 
similar to reported data in the literature.
94
 This would explain why the Test groups 
maintained their biomechanical qualities through Day 56 to that of Day 0 controls. 
Correlations were seen in the histological staining and biochemical results of 
OCA samples. Among femoral condyle OCAs sections, the loss of cells in the 
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superficial layer of OCAs stored in 37°C Test media at Day 56 corresponded with a 
decrease in cell viability using CellTracker™ Green CMFDA and ethidium 
homodimer-1. Also, the significant drop in GAG content at Day 56 of OCAs stored in 
37°C Test media from Day 0 levels as measured with the DMMB assay corresponded 
well with the decreased T-blue staining of those samples at Day 56. Trichrome 
staining was maintained through storage and this correlated with the biochemical 
measurements. In tibial plateau histologic staining there were some similar 
correlations to biochemical measurements. There were some minor degenerative 
changes noted with H&E staining at Day 56. The most pronounced correlation was 
again in the T-blue staining, there was profoundly less staining in OCAs stored in 4°C 
Test and 37°C Test media which correlated to the significantly less than Day 0 levels 
of GAG found using the DMMB assay. As found with femoral condyle OCA section 
Trichrome staining, the staining was maintained throughout storage which correlated 
with the biochemical data.   
Immunohistochemistry helped confirm the type of collagen measured 
biochemically and the production of proteoglycan through the different layers of 
cartilage. The samples indicate that collagen II was not replaced with collagen I 
during storage because of the strong green fluorescence of Collagen II throughout 
storage. Proteoglycan was also evident upon examination of all samples. 
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CHAPTER 3: FUTURE DIRECTIONS 
 
 
The findings in the current study can be translated to human OCA research as 
animal models are commonly used in orthopedic research. Research is ongoing in our 
laboratory with different storage temperatures and supplements to storage media. 
Despite the 37°C Control media with basic supplementation proved to be superior in 
this particular study further research needs to be done to assess the best media 
preparation for tissue preservation. Unpublished data from our laboratory suggests 
that one of the supplements of the Test media actively kills chondrocytes. This is 
logical considering the time-dependent decrease in cell viability of OCAs stored in 
the 37°C Test media. Studies have shown that apoptotic pathways are upregulated 
during storage, therefore, many media supplements to inhibit apoptosis to prolong 
storage and tissue quality have been investigated.
89
 These studies have shown mixed 
results so far.
86,90
  
Currently our lab is attempting to identify a panel of cytokines that are released 
from OCAs into the storage media that would allow tissue bankers to assess the 
viability of the tissue prior to transplantation. Further study will be needed to 
determine which cytokines are upregulated by healthy tissue during storage. Research 
is also ongoing using alamarBlue to assess tissue viability without disturbing it during 
storage. 
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Most importantly, we have begun in vivo canine studies transplanting OCAs at 
Day 28 and 56 to assess their efficacy and the effect of storage on the allografts. Time 
will tell which storage media composition yields the best clinical results in vivo. 
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TABLES 
 
 
 
Table 7: Average percent chondrocyte viability of femoral condyle and tibial plateau 
OCA from Day 0 Controls ± SEM 
 
 Day 0 
Femoral condyle 77.23482±3.907 
Tibial plateau 85.83275±2.107 
 
 
Table 8: Average percent chondrocyte viability of femoral condyle OCA from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media ± SEM. 
 
 Day 28 Day 56 
4C Control 39.73122±9.507 27.38466±11.882 
37C Control 76.39993±2.675 69.55185±3.253 
4C Test 33.32883±12.435 23.27365±7.376 
37C Test 56.51616±9.739 27.80691±10.192 
 
 
Table 9: Average percent chondrocyte viability of tibial plateau OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media ± SEM. 
 Day 28 Day 56 
4C Control 50.34013±7.944 44.90302±8.84 
37C Control 78.05448±7.934 71.59964±5.549 
4C Test 35.2419±9.982 27.68835±5.526 
37 Test 66.21004±3.334 40.24481±8.551 
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Table 10: Average total tissue GAG content of femoral condyle and tibial plateau OCA 
from Day 0 Controls. Values reported at µg GAG/mg dry weight ± SEM. 
 
 Day 0 
Femoral condyle 107.7861±7.304 
Tibial plateau 137.7271±9.7 
 
 
 
Table 11: Average total tissue GAG content of femoral condyle OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values reported at µg GAG/mg 
dry weight ± SEM. 
 
 
 
Table 12: Average total tissue GAG content of tibial plateau OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values reported at µg GAG/mg 
dry weight ± SEM. 
 Day 28 Day 56 
4C Control 171.2841±10.095 152.3022±16.362 
37C Control 114.1398±12.558 128.2485±15.465 
4C Test 143.9543±14.799 83.25958±16.189 
37 Test 107.9645±19.546 70.95953±10.651 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Day 28 Day 56 
4C Control 122.8825±19.743 133.1977±25.756 
37C Control 111.6715±14.021 143.1201±30.69 
4C Test 110.1583±24.073 62.03961±26.277 
37 Test 83.16426±19.015 45.47233±13.401 
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Table 13: Average total media GAG content of femoral condyle OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values reported as µg GAG 
normalized to media volume ± SEM. 
 
Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56 
4C 
854.9848
±172.532 
477.7734
±78.762 
579.1158
±114.09 
332.0003
±75.346 
278.5124
±60.473 
346.1762
±110.025 
317.036±
112.893 
385.8885
±112.52 
37C 
5753.316
±948.84 
3833.465
±652.417 
3029.647
±420.621 
2501.676
±360.597 
3269.766
±715.03 
2349.219
±297.125 
2159.224
±277.83 
2960.621
±580.85 
4T 
2708.496
±500.802 
2065.177
±317.792 
2567.112
±414.895 
1463.629
±227.772 
1808.188
±432.89 
1413.792
±364.126 
956.9396
±206.414 
1229.131
±326.86 
37T 
6287.376
±942.359 
6127.096
±921.607 
6987.114
±1025.93 
5197.367
±759.837 
5674.968
±2120.3 
4102.255
±1687.68 
2831.696
±1174.82 
2360.426
±758.61 
 
 
 
Table 14: Average total media GAG content of tibial plateau OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values reported as µg GAG 
normalized to media volume ± SEM. 
 
Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56 
4C 
1033.86
±275.9 
540.4845
±103.51 
573.419
±105.46 
418.7695
±103.25 
529.1133
±207.04 
425.5679
±121.84 
344.6821
±72.096 
352.0595
±156.41 
37C 
6894.78
±1253.1 
3882.545
±897.335 
3080.33
±378.57 
2507.286
±344.72 
2283.831
±508.77 
2292.311
±464.11 
1993.245
±387.54 
2526.65
±472.29 
4T 
2410.77
±350.61 
1470.071
±250.46 
1813.59
±295.81 
1203.139
±175.88 
1324.185
±296.00 
1078.968
±296.34 
661.8652
±184.33 
1014.907
±269.38 
37T 
4926.32
±1021.9 
5657.802
±754.86 
7002.99
±943.73 
5050.089
±663.89 
6211.998
±1571.7 
5148.572
±1306.3 
3653.359
±889.9 
4917.372
±1289.6 
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Table 15: Average total tissue HP content of femoral condyle and tibial plateau OCA 
from Day 0 Controls. Values reported at µg HP/mg dry weight ± SEM. 
 Day 0 
Femoral condyle 11.91843±1.227 
Tibial plateau 40.6185±2.877 
 
 
Table 16: Average total tissue HP content of femoral condyle OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values reported at µg HP/mg dry 
weight ± SEM. 
 Day 28 Day 56 
4C Control 4.966775±3.385 8.60919±3.12 
37C Control 4.604439±2.615 7.295832±0.87 
4C Test 4.418919±2.351 8.66096±1.219 
37 Test 4.29748±2.08 7.799685±13.4 
 
 
 
Table 17: Average total tissue HP content of tibial plateau OCA from 4°C Control, 37°C 
Control, 4°C Test, and 37°C Test storage media. Values reported at µg HP/mg dry weight 
± SEM. 
 Day 28 Day 56 
4C Control 3.601321±4.991 7.227135±3.991 
37C Control 4.472227±0.637 5.962451±1.281 
4C Test 4.455807±1.466 7.810117±1.967 
37 Test 5.746179±4.966 9.727519±3.903 
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Table 18:Average total media NO release from femoral condyle OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values are reported as µg NO 
normalized to media volume ± SEM. 
 Week 1 Week 4 Week 8 
4C Control 736.6113±68.073 686.2217±61.996 598.1128±104.521 
37C Control 1318.999±207.125 784.2455±80.748 634.9471±127.484 
4C Test 874.7158±73.666 766.5193±62.189 699.6534±113.744 
37C Test 1039.877±136.857 849.5451±106.753 611.9189±159.639 
 
Table 19: Average total media NO release from tibial plateau OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values are reported as µg NO 
normalized to media volume ± SEM. 
 Week 1 Week 4 Week 8 
4C Control 809.2675±56.491 744.926±58.811 689.932±101.887 
37C Control 1281.37±110.078 883.7199±71.759 750.1224±120.607 
4C Test 926.1565±93.647 873.754±96.101 763.3694±130.691 
37C Test 1223.406±133.405 1089.2±87.283 856.1071±132.931 
 
Table 20: Average total media PGE2 release from femoral condyle OCA from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values are reported at pg 
PGE2 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 54675.95±7464.59 21185.26±3764.99 7759.531±1944.25 
37C Control 212267.5±142181 37794.3±5278.64 25875.64±7204.38 
4C Test 82508.65±23370.4 6880.983±999.13 5455.854±1175.76 
37C Test 67104.18±8594.49 91327.57±37739.3 20761.6±7284.24 
 
Table 21: Average total media PGE2 release from tibial plateau OCA from 4°C Control, 
37°C Control, 4°C Test, and 37°C Test storage media. Values are reported at pg PGE2 
normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 75787.15±11438.8 22226.35±3997.93 8560.867±1649.8 
37C Control 153910.7±76036.2 37918.52±4935.16 29954.85±3470.33 
4C Test 65416.93±8060.61 5705.997±1003.75 5811.483±1290.86 
37C Test 75811.44±6889.43 74898.33±9393.39 35580.02±9315.97 
 
57 
 
Table 22: Average total MMP-2 release into media from femoral condyle OCA from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported at pg 
MMP-2 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 0 0 0 
37C Control 153958.5±37736.5 292994.9±53631.3 263089.4±45634.4 
4C Test 0 13990.1±12921.9 0 
37C Test 59948.38±16676.8 130577.4±59874.8 123596.8±51162.3 
 
 
 
Table 23: Average total MMP-3 release into media from femoral condyle OCA from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg 
MMP-3 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 94571.89±16082.5 54393.95±12073 19232.52±3071.65 
37C Control 177446.9±27195.5 142543±35775.5 100779.7±26088.7 
4C Test 117673±13986.2 51958.3±6008.09 12129±2633.83 
37C Test 135019.8±26479.8 77571.01±33822.1 73335.35±30777.1 
 
 
 
Table 24: Average total MMP-13 release into media from femoral condyle OCA from 
4°C Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as 
pg MMP-13 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 385.2±385.2 489.06±489.06 0 
37C Control 105142.9±62010 143367.2±81277.5 74079.6±58175.2 
4C Test 6991.14±5080.11 546.48±546.48 0 
37C Test 16273.65±13130.9 10764.64±5874.13 6064.263±3593.61 
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Table 25: Average total KC release into media from femoral condyle OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg KC 
normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 35839.64±12510.4 782.3425±293.94 0 
37C Control 161730.4±80531.9 54114.84±33164.7 43393.61±38258.1 
4C Test 71423.98±17239.5 1401.487±483.369 196.5833±80.828 
37C Test 93415.49±24005.4 10779.41±6945.65 542.2523±230.394 
 
 
Table 26: Average total IL-6 release into media from femoral condyle OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg IL-
6 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 0 134.005±134.005 0 
37C Control 18058.86±16332 260.4001±222.548 203.9278±203.928 
4C Test 178.2294±178.229 0 0 
37C Test 322.7981±322.798 16.36226±16.362 0 
 
 
Table 27: Average total IL-8 release into media from femoral condyle OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg IL-
8 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 84703.56±27.558.1 8851.474±1781.41 3908.329±690.816 
37C Control 616286.9±155837 62776.87±32056.7 248675±230742 
4C Test 147783.3±35381.9 52677.65±19246.2 4739.466±589.113 
37C Test 213769.4±38113.8 76329.05±30401.3 9537.231±3795.2 
 
 
Table 28: Average total MCP-1 release into media from femoral condyle OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg 
MCP-1 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 17117.94±6808.09 223.0721±137.737 0 
37C Control 337971.8±201621 112706.3±35524.7 779136.5±702580 
4C Test 36880.68±11813.7 105476±32909.4 0 
37C Test 55999.71±10675.1 12365.87±5452.89 2294.431±1243.35 
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Table 29: Average total KC release into media from tibial plateau OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg KC 
normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 55743.58±14448.02 435.7188±120.984 0 
37C Control 206594±27486.8 24963.64±7651.155 8897.978±4097.876 
4C Test 70108.81±19238.95 1173.049±456.11 161.3898±99.792 
37C Test 151775.3±22108.21 26087.22±3784.482 3307.926±1479.349 
 
 
Table 30: Average total IL-6 release into media from tibial plateau OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg IL-
6 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 170.5721±105.471 0 0 
37C Control 3226.535±1761.21 0 0 
4C Test 103.7029±67.112 0 0 
37C Test 1198.069±1088.43 0 0 
 
Table 31: Average total IL-8 release into media from tibial plateau OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg IL-
8 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 122942.1±31795.2 6332.919±865.342 4799.72±721.303 
37C Control 856149.7±155412 83794.43±9031.85 36872.8±7051.5 
4C Test 144207±30915.6 9492.261±2378.37 13339.88±7626.24 
37C Test 320935.5±80297.6 194190.8±59767.1 26141.69±8641.95 
 
Table 32: Average total MCP-1 release into media from tibial plateau OCAs from 4°C 
Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported as pg 
MCP-1 normalized to media volume ± SEM. 
 Day 7 Day 28 Day 56 
4C Control 17845.25±6534.05 0 0 
37C Control 196833.7±37990.6 148236.6±15031.4 118378.3±13034.1 
4C Test 21078.91±7574.95 0 24384.28±23459.1 
37C Test 66618.41±15004 29127.07±9645.46 8687.532±2765.91 
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Table 33: Average elastic and dynamic modulus of femoral condyle OCA full thickness 
cartilage Day 0 Controls. Values reported as MPa ± SEM. 
 
 
 
 
Table 34: Average elastic and dynamic modulus of tibial plateau OCA full thickness 
cartilage Day 0 Controls. Values reported as MPa ± SEM. 
 Day 0 
Elastic Modulus 5.0272±0.8811 
Dynamic Modulus 5.25612±0.6445 
 
Table 35: Average elastic modulus of full thickness cartilage from femoral condyle 
OCAs from 4°C Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values 
reported as MPa ± SEM. 
 Day 28 Day 56 
4C Control 3.6438±0.4647 4.7890±0.6145 
37C Control 2.8953±0.7688 5.0866±1.0182 
4C Test 3.4082±0.3617 5.9492±0.4939 
37 Test 4.3353±1.0453 5.9106±1.0773 
 
Table 36: Average dynamic modulus of full thickness cartilage from femoral condyle 
OCAs from 4°C Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values 
reported as MPa ± SEM. 
 Day 28 Day 56 
4C Control 3.5980±0.6123 6.4207±0.8562 
37C Control 3.7219±0.5577 7.9304±1.3175 
4C Test 4.0177±0.8681 7.3900±0.5646 
37 Test 4.9933±1.2246 6.5325±1.5861 
 
 
 Day 0 
Elastic Modulus 7.0003±0.9511 
Dynamic Modulus 6.8636±1.3677 
61 
 
Table 37: Average elastic modulus of full thickness cartilage from tibial plateau OCAs 
from 4°C Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported 
as MPa ± SEM. 
 Day 28 Day 56 
4C Control 2.9583±0.5495 3.9255±1.1505 
37C Control 2.4948±0.4214 6.9864±1.6632 
4C Test 4.2700±0.6932 7.6691±1.3883 
37 Test 3.3419±1.0252 10.0256±2.6771 
 
Table 38: Average dynamic modulus of full thickness cartilage from tibial plateau OCAs 
from 4°C Control, 37°C Control, 4°C Test, and 37°C Test storage media. Values reported 
as MPa ± SEM. 
 Day 28 Day 56 
4C Control 3.6327±0.5309 4.9548±0.6562 
37C Control 2.2407±0.5029 5.3685±1.9378 
4C Test 3.7415±0.7653 7.2236±1.5106 
37 Test 3.6940±1.2916 10.0140±3.2835 
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FIGURES 
 
 
Figure 1: Chondrocyte viability (±SEM) of femoral condyles at Day 0, 28, and 56. At 
Day 28(*), OCAs from Day 0 and stored in 37°C Control media had significantly higher  
viability than 4°C Control and Test media. At Day 56(#), OCAs from Day 0 and stored in 
37°C Control media had significantly higher viability than all other groups. (p<0.05) 
 
Figure 2: Chondrocyte viability (±SEM) of tibial plateaus at Day 0, 28, and 56. At Day 
28(*), OCAs stored in 37°C Control media had significantly higher viability than both 4° 
storage groups, those in 37°C Test media had significantly higher viability than 4°C Test 
media, and Day 0 OCAs had higher viability than both 4° storage groups and 37°C Test 
media. At Day 56(#), OCAs stored in 37°C Control media maintained higher viability 
than all other storage groups yet no storage group was able to maintain Day 0 viability. 
(p<0.05) 
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Figure 3: Representative images of chondrocyte viability from Day 0 Controls. (10X 
magnification) 
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Figure 4: Representative images of femoral condyle chondrocyte viability from Day 28. 
(10X magnification) 
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Figure 5: Representative images of femoral condyle chondrocyte viability from Day 56. 
(10X magnification) 
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Figure 6: Representative images of tibial plateau chondrocyte viability at Day 28. (10X 
magnification) 
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Figure 7: Representative images of tibial plateau chondrocyte viability at Day 56. (10X 
magnification) 
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Figure 8: Tissue GAG content (±SEM) of femoral condyles. Values are reported as µg 
GAG/mg dry weight full thickness cartilage. At Day 56(*), OCAs stored in 37°C Test 
media had significantly less GAG than those stored in 4°C and 37°C Control media and 
Day 0 controls. (p<0.05) 
 
 
Figure 9: Tissue GAG content (±SEM) of tibial plateaus. Values are reported as µg 
GAG/mg dry weight full thickness cartilage. At Day 28(*), OCAs stored in 4°C Control 
media had significantly more GAG than both groups stored at 37°C. At Day 56(#), OCAs 
stored in 4°C Control media had significantly higher GAG content than those stored in 
4°C Test and 37°C Test media, GAG content was significantly higher in 37°C Control 
than 37°C Test, and Day 0 levels of GAG were significantly higher than 4°C Test and 
37°C Test media. (p<0.05) 
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Figure 10: Media GAG release (±SEM) of femoral condyles. Values are reported as µg 
GAG and normalized to media volume. (a - 37°C Test>37°C Control,  b - 37°C Test>4°C 
Control, c - 37°C Test>4°C Test, d - 37°C Control>4°C Control, e - 37°C Control>4°C 
Test, f - 4°C Test>4°C Control) p<0.05 
 
Figure 11: Media GAG release (±SEM) of tibial plateaus. Values are reported as µg GAG 
and normalized to media volume. (a - 37°C Test>37°C Control, b - 37°C Test>4°C 
Control, c - 37°C Test>4°C Test, d - 37°C Control>4°C Control, e - 37°C Control>4°C 
Test, f - 4°C Test>4°C Control) p<0.05 
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Figure 12: Total tissue HP content (±SEM) of femoral condyles. Values are reported as 
µg HP/mg dry weight of full thickness cartilage. No significant differences. 
 
Figure 13: Total tissue HP content (±SEM) of tibial plateaus. Values are reported as µg 
HP/mg dry weight of full thickness cartilage. At Day 28(*), OCAs stored in 37°C Test 
media had significantly higher HP content than 37°C Control and Day 0. At Day 56(#), 
OCAs stored in 4°C Test media had significantly more HP than Day 0. (p<0.05) 
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Figure 14:Total media nitric oxide release (±SEM) from femoral condyles. Values are 
reported as µg NO normalized to the media volume. At Day 7(*), OCAs stored in 37°C 
Control had significantly more NO release than both groups at 4°C. (p<0.05) 
 
Figure 15: Total media nitric oxide release (±SEM) from tibial plateaus. Values are 
reported as µg NO normalized to the media volume. At Day 7(*), OCAs stored in 37°C 
Control media had significantly more NO release than both groups at 4°C and 37°C Test 
media had significantly more NO release than 4°C Control. At Day 28, the OCAs stored 
in 37°C Test media had significantly more NO release than those stored in 4°C Control. 
(p<0.05) 
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Figure 16: Total media PGE2 release (±SEM) from femoral condyles. Values are 
reported at pg PGE2 normalized to media volume. At Day 28(*), OCAs stored in 37°C 
Control had significantly higher PGE2 release than both 4°C groups. OCAs stored in 
37°C Test media and 4°C Control media also had higher PGE2 release than 4°C Test 
media. At Day 56(#), OCAs stored in 37°C Control media had higher PGE2 release than 
both groups stored at 4°C. ( p<0.05) 
 
Figure 17: Total media PGE2 release (±SEM) from tibial plateaus. Values are reported at 
pg PGE2 normalized to media volume. At Day 28(*), OCAs stored in 37°C Test media 
had significantly higher PGE2 release than all other groups. Also, those stored in 37°C 
Control had significantly higher PGE2 release than both 4°C groups. Finally, release was 
statistically higher from OCAs in 4°C Control than 4°C Test media. At Day 56(#), OCAs 
stored in 37°C Control had significantly higher PGE2 release than both 4°C groups. 
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Figure 18: Media MMP release (±SEM) into media from femoral condyles. Values are 
reported at pg MMP normalized to media volume. (a – 37°C Control > 4°C groups, b - 
37°C Test > 4°C groups, c - 37°C Control > 4°C Control, d - 37°C Control > all groups) 
p<0.05  
0
100000
200000
300000
400000
Day 7 Day 28 Day 56
p
g 
M
M
P
-2
MMP-2
4C Control
37C Control
4C Test
37C Test
a,b
a
a
0
50000
100000
150000
200000
250000
Day 7 Day 28 Day 56
p
g 
M
M
P
-3
MMP-3
4C Control
37C Control
4C Test
37C Test
a
a
c
-50000
0
50000
100000
150000
200000
250000
Day 7 Day 28 Day 56
p
g 
M
M
P
-1
3
MMP-13
4C Control
37C Control
4C Test
37C Test
a
a
d
74 
 
 
 
 
Figure 19: Media cytokine release (±SEM) from femoral condyles. Values are reported as 
pg cytokine normalized to media volume. ( a – 37°C Control > 4°C Control, b - 37°C 
Control > 4°C groups, c - 37°C Control > all groups, d - 37°C Test > 4°C Control, e - 4°C 
Test > 4°C Control, f - 37°C Control > 37°C Test, g - 4°C Test > 37°C Test) p<0.05 
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Figure 20: Media cytokine release (±SEM) from tibial plateaus. Values are reported as pg 
cytokine normalized to media volume. (a - 37°C Control > 4°C groups, b - 37°C Test > 
4°C groups, c - 37°C Test > 4°C Control, d - 37°C Control > all groups, e - 37°C Test > 
4°C Test, f - 37°C Test > all groups, g - 37°C Test > 4°C Control) p<0.05 
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Figure 21: Biomechanical properties, elastic and dynamic moduli (±SEM), of femoral 
condyle full thickness cartilage from Day 0 Controls, 4°C Control, 37°C Control, 4°C 
Test, 37°C Test media at Day 28 and 56. Values reported as MPa. At Day 28(*), the Day 
0 Control had significantly higher elastic modulus than OCAs stored in 4°C Control, 
37°C Control, and 4°C Test media. Also at Day 28(*), the Day 0 Control had 
significantly higher dynamic modulus than OCAs stored in 37°C Control. (p<0.05) 
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Figure 22: Biomechanical properties, elastic and dynamic moduli (±SEM), of tibial 
plateau full thickness cartilage from Day 0 Controls, 4°C Control, 37°C Control, 4°C 
Test, 37°C Test media at Day 28 and 56. Values are reported as MPa. At Day 28(*), the 
Day 0 Control had significantly higher elastic modulus than OCAs stored in 37°C Control 
media. Also at Day 28(*), the Day 0 Control had significantly higher dynamic modulus 
than OCAs stored in 37°C Control. At Day 56(#), the 37°C Control had significantly 
lower dynamic modulus than both 4°C Test and 37°C Test media. (p<0.05) 
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Figure 23: Representative images from Day 0 femoral condyles (10X magnification)  
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Figure 24: Representative images of Day 0 tibial plateaus (10X magnification) 
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4°C Control        37°C Control 
 
 
 
 
4°C Test        37°C Test 
 
Figure 25: H&E stain of representative images of femoral condyles at Day 28 (10X 
magnification) 
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4°C Control        37°C Control 
 
 
 
 
 
 
 
 
 4°C Test        37°C Test 
Figure 26: T-blue stain of representative images of femoral condyles at Day 28 (10X 
magnification)  
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4°C Control       37°C Control 
 
 
 
 
 
 
 
4°C Test        37°C Test 
Figure 27: Trichrome stain of representative images of femoral condyles at Day 28 (10X 
magnification) 
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4°C Control        37°C Control 
 
 
4°C Test        37°C Test 
 
Figure 28: H&E stain of representative images of femoral condyles at Day 56 (10X 
magnification) 
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4°C Control       37°C Control 
 
 
4°C Test       37°C Test 
 
Figure 29: T-blue stain of representative images of femoral condyles at Day 56 (10X 
magnification) 
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4°C Control       37°C Control 
 
 
 
 
 
 
 
4°C Test       37°C Test  
Figure 30: Trichrome stain of representative images of femoral condyles at Day 56 (10X 
magnification)  
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4°C Control      37°C Control 
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Figure 31: Representative images of H&E stained tibial plateaus at Day 28 (10X 
magnification) 
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4°C Control      37°C Control    
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Figure 32: Representative T-blue stained tibial plateaus at Day 28 (10X magnification) 
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4°C Control      37°C Control 
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Figure 33: Representative images of Trichrome stained tibial plateaus at Day 28 (10X 
magnification) 
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4°C Control      37°C Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4°C Test      37°C Test 
 
 
Figure 34: Representative images of H&E stained tibial plateaus at 56 days. (10X 
magnification) 
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Figure 35: Representative images of T-blue stained tibial plateaus at Day 56 (10X 
magnification) 
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4°C Control       37°C Control 
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Figure 36: Representative images of Trichrome stained tibial plateaus at Day 56. (10X 
magnification)       
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Figure 37: Representative IHC images of Day 0 Controls (20X magnification) 
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Figure 38: Representative IHC images of femoral condyles at Day 28 (20X 
magnification) 
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Figure 39: Representative IHC images of femoral condyles at Day 56 (20X 
magnification) 
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Figure 40: Representative IHC images of tibial plateaus at Day 28 (20X magnification) 
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Figure 41: Representative IHC images of tibial plateaus at Day 56 (20X magnification) 
 
 
97 
 
 
 
 
 
 
 
 
VITA 
 
 
 
Joseph Thomas Garrity was born on August 14, 1985 in Moline, Illinois. He 
graduated from Orion High School in 2004. From there he decided to attend the 
University of Missouri to continue wrestling and pursue a Bachelor of Science in 
Biological Sciences which he received in 2008. Upon graduation he received the Dr. 
Prentice Gautt Postgraduate Scholarship from the Big XII Conference and chose to use 
this to pursue a Master of Science in Biomedical Sciences with an emphasis on 
Pathobiology. He is currently a second year medical student at the University of Missouri 
School of Medicine. 
 
  
98 
 
BIBLIOGRAPHY 
 
 
1. Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage 
injuries: a review of 31,516 knee arthroscopies. Arthroscopy 1997;13:456-60. 
2. Hjelle K, Solheim E, Strand T, Muri R, Brittberg M. Articular cartilage defects in 
1,000 knee arthroscopies. Arthroscopy 2002;18:730-4. 
3. Widuchowski W, Widuchowski J, Trzaska T. Articular cartilage defects: study of 
25,124 knee arthroscopies. Knee 2007;14:177-82. 
4. Aroen A, Loken S, Heir S, et al. Articular cartilage lesions in 993 consecutive knee 
arthroscopies. The American Journal of Sports Medicine 2004;32:211-5. 
5. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of 
arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 
2008;58:26-35. 
6. Mankin HJ. The response of articular cartilage to mechanical injury. J Bone Joint 
Surg Am 1982;64:460-6. 
7. Buckwalter JA. Articular cartilage injuries. Clinical Orthopaedics and Related 
Research 2002:21-37. 
8. Martin JA, Buckwalter JA. The role of chondrocyte-matrix interactions in 
maintaining and repairing articular cartilage. Biorheology 2000;37:129-40. 
9. O'Driscoll SW. The healing and regeneration of articular cartilage. J Bone Joint 
Surg Am 1998;80:1795-812. 
10. Duda GN, Maldonado ZM, Klein P, Heller MO, Burns J, Bail H. On the influence of 
mechanical conditions in osteochondral defect healing. J Biomech 2005;38:843-51. 
11. Alleyne KR, Galloway MT. Management of osteochondral injuries of the knee. 
Clinics in Sports Medicine 2001;20:343-64. 
12. Jackson R. Arthroscopic Treatment of Degenerative Arthritis. New York: Raven 
Press; 1991. 
13. Chang RW, Falconer J, Stulberg SD, Arnold WJ, Manheim LM, Dyer AR. A 
randomized, controlled trial of arthroscopic surgery versus closed-needle joint lavage 
for patients with osteoarthritis of the knee. Arthritis Rheum 1993;36:289-96. 
14. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic 
surgery for osteoarthritis of the knee. N Engl J Med 2002;347:81-8. 
15. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of 
microfracture for traumatic chondral defects of the knee: average 11-year follow-up. 
Arthroscopy 2003;19:477-84. 
99 
 
16. Frisbie DD, Oxford JT, Southwood L, et al. Early events in cartilage repair after 
subchondral bone microfracture. Clinical Orthopaedics and Related Research 2003:215-
27. 
17. Kreuz PC, Erggelet C, Steinwachs MR, et al. Is microfracture of chondral defects 
in the knee associated with different results in patients aged 40 years or younger? 
Arthroscopy 2006;22:1180-6. 
18. Willers C, Partsalis T, Zheng MH. Articular cartilage repair: procedures versus 
products. Expert Rev Med Devices 2007;4:373-92. 
19. Aeschlimann D, Lyons P, Masterlark T, Hayashi K, Graf B, Vanderby R. Repair of 
cartilage defects with autogenous osteochondral transplants (mosaicplasty) in a sheep 
model. In: 46th Annual Meeting, Orthopaedic Research Society; 2000; Orlando; 2000. p. 
183. 
20. Archibeck MJ, Jacobs JJ, Roebuck KA, Glant TT. The basic science of 
periprosthetic osteolysis. Instr Course Lect 2001;50:185-95. 
21. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic 
science. Clinical Orthopaedics and Related Research 2001:71-7. 
22. Czitrom AA, Keating S, Gross AE. The viability of articular cartilage in fresh 
osteochondral allografts after clinical transplantation. J Bone Joint Surg Am 
1990;72:574-81. 
23. Convery FR, Akeson WH, Amiel D, Meyers MH, Monosov A. Long-term survival of 
chondrocytes in an osteochondral articular cartilage allograft. A case report. J Bone Joint 
Surg Am 1996;78:1082-8. 
24. Jamali AA, Hatcher SL, You Z. Donor cell survival in a fresh osteochondral 
allograft at twenty-nine years. A case report. J Bone Joint Surg Am 2007;89:166-9. 
25. Gross AE, Kim W, Las Heras F, Backstein D, Safir O, Pritzker KP. Fresh 
osteochondral allografts for posttraumatic knee defects: long-term followup. Clinical 
Orthopaedics and Related Research 2008;466:1863-70. 
26. Lexer E. Joint transplantations and arthroplasty. The Journal of Surgery, 
Gynecology, and Obstetrics 1925;40:782-809. 
27. Mankin HJ, Fogelson FS, Thrasher AZ, Jaffer F. Massive resection and allograft 
transplantation in the treatment of malignant bone tumors. N Engl J Med 
1976;294:1247-55. 
28. Gross AE, McKee NH, Pritzker KP, Langer F. Reconstruction of skeletal deficits at 
the knee. A comprehensive osteochondral transplant program. Clinical Orthopaedics 
and Related Research 1983:96-106. 
29. Meyers MH, Jones RE, Bucholz RW, Wenger DR. Fresh autogenous grafts and 
osteochondral allografts for the treatment of segmental collapse in osteonecrosis of the 
hip. Clinical Orthopaedics and Related Research 1983:107-12. 
30. Williams RJ, 3rd, Dreese JC, Chen CT. Chondrocyte survival and material 
properties of hypothermically stored cartilage: an evaluation of tissue used for 
osteochondral allograft transplantation. The American Journal of Sports Medicine 
2004;32:132-9. 
100 
 
31. Jackson DW, Scheer MJ, Simon TM. Cartilage substitutes: overview of basic 
science and treatment options. J Am Acad Orthop Surg 2001;9:37-52. 
32. Bugbee WD, Convery FR. Osteochondral allograft transplantation. Clinics in 
Sports Medicine 1999;18:67-75. 
33. Latterman C, Romine SE. Osteochondral allografts: state of the art. Clinics in 
Sports Medicine 2009;28:285-301. 
34. Gortz S, Bugbee WD. Allografts in articular cartilage repair. Instr Course Lect 
2007;56:469-80. 
35. McDermott AG, Langer F, Pritzker KP, Gross AE. Fresh small-fragment 
osteochondral allografts. Long-term follow-up study on first 100 cases. Clinical 
Orthopaedics and Related Research 1985:96-102. 
36. Gortz S, De Young AJ, Bugbee WD. Fresh osteochondral allografting for steroid-
associated osteonecrosis of the femoral condyles. Clinical Orthopaedics and Related 
Research 2010;468:1269-78. 
37. Oakeshott RD, Farine I, Pritzker KP, Langer F, Gross AE. A clinical and histologic 
analysis of failed fresh osteochondral allografts. Clinical Orthopaedics and Related 
Research 1988:283-94. 
38. McGoveran BM, Pritzker KP, Shasha N, Price J, Gross AE. Long-term chondrocyte 
viability in a fresh osteochondral allograft. The Journal of Knee Surgery 2002;15:97-100. 
39. Rodrigo JJ, Thompson E, Travis C. Deep-freezing versus 4 degrees preservation of 
avascular osteocartilaginous shell allografts in rats. Clinical Orthopaedics and Related 
Research 1987:268-75. 
40. Glenn RE, Jr., McCarty EC, Potter HG, Juliao SF, Gordon JD, Spindler KP. 
Comparison of fresh osteochondral autografts and allografts: a canine model. The 
American Journal of Sports Medicine 2006;34:1084-93. 
41. Pennock AT, Robertson CM, Wagner F, Harwood FL, Bugbee WD, Amiel D. Does 
subchondral bone affect the fate of osteochondral allografts during storage? The 
American Journal of Sports Medicine 2006;34:586-91. 
42. Gortz S, Bugbee WD. Fresh osteochondral allografts: graft processing and clinical 
applications. The Journal of Knee Surgery 2006;19:231-40. 
43. LaPrade RF, Botker J, Herzog M, Agel J. Refrigerated osteoarticular allografts to 
treat articular cartilage defects of the femoral condyles. A prospective outcomes study. J 
Bone Joint Surg Am 2009;91:805-11. 
44. Langer F, Gross AE. Immunogenicity of allograft articular cartilage. J Bone Joint 
Surg Am 1974;56:297-304. 
45. Sirlin CB, Brossmann J, Boutin RD, et al. Shell osteochondral allografts of the 
knee: comparison of mr imaging findings and immunologic responses. Radiology 
2001;219:35-43. 
46. Getgood A, Bollen S. What tissue bankers should know about the use of allograft 
tendons and cartilage in orthopaedics. Cell Tissue Bank 2009. 
47. Friedlaender GE, Horowitz MC. Immune responses to osteochondral allografts: 
nature and significance. Orthopedics 1992;15:1171-5. 
101 
 
48. Bastian JD, Egli RJ, Ganz R, Hofstetter W, Leunig M. Chondrocytes within 
osteochondral grafts are more resistant than osteoblasts to tissue culture at 37 degrees 
C. J Invest Surg 2011;24:28-34. 
49. Stevenson S, Shaffer JW, Goldberg VM. The humoral response to vascular and 
nonvascular allografts of bone. Clinical Orthopaedics and Related Research 1996:86-95. 
50. Kandel RA, Gross AE, Ganel A, McDermott AG, Langer F, Pritzker KP. 
Histopathology of failed osteoarticular shell allografts. Clinical Orthopaedics and Related 
Research 1985:103-10. 
51. Phipatanakul WP, VandeVord PJ, Teitge RA, Wooley PH. Immune response in 
patients receiving fresh osteochondral allografts. Am J Orthop (Belle Mead NJ) 
2004;33:345-8. 
52. Williams SK, Amiel D, Ball ST, et al. Analysis of cartilage on a cellular level in fresh 
osteochondral allograft retrievals. The American Journal of Sports Medicine 
2007;35:2022-32. 
53. McAllister DR, Joyce MJ, Mann BJ, Vangsness CT, Jr. Allograft update: the current 
status of tissue regulation, procurement, processing, and sterilization. The American 
Journal of Sports Medicine 2007;35:2148-58. 
54. Williams RJ, Ranawat AS, Potter HG, Carter T, Warren RF. Fresh stored allografts 
for the treatment of osteochondral defects of the knee. The Journal of Bone and Joint 
Surgery 2007;89:718-26. 
55. Joyce MJ, Greenwald AS, Boden S, Brubaker S, Heim CS. Musculoskeletal 
Allograft Tissue Safety. In: American Academy of Orthopaedic Surgeons; 2008; San 
Francisco, CA; 2008. 
56. Ball ST, Amiel D, Williams SK, et al. The effects of storage on fresh human 
osteochondral allografts Clinical Orthopaedics and Related Research 2004;418:246-52. 
57. Williams JM, Virdi AS, Pylawka TK, Edwards RB, 3rd, Markel MD, Cole BJ. 
Prolonged-fresh preservation of intact whole canine femoral condyles for the potential 
use as osteochondral allografts. J Orthop Res 2005;23:831-7. 
58. Davidson PA, Rivenburgh DW, Dawson PE, Rozin R. Clinical, histologic, and 
radiographic outcomes of distal femoral resurfacing with hypothermically stored 
osteoarticular allografts. The American Journal of Sports Medicine 2007;35:1082-90. 
59. Malinin T, Temple HT, Buck BE. Transplantation of osteochondral allografts after 
cold storage. J Bone Joint Surg Am 2006;88:762-70. 
60. Enneking WF, Campanacci DA. Retrieved human allografts : a clinicopathological 
study. J Bone Joint Surg Am 2001;83-A:971-86. 
61. Enneking WF, Mindell ER. Observations on massive retrieved human allografts. J 
Bone Joint Surg Am 1991;73:1123-42. 
62. Judas F, Rosa S, Teixeira L, Lopes C, Ferreira Mendes A. Chondrocyte viability in 
fresh and frozen large human osteochondral allografts: effect of cryoprotective agents. 
Transplant Proc 2007;39:2531-4. 
63. Stevenson S, Dannucci GA, Sharkey NA, Pool RR. The fate of articular cartilage 
after transplantation of fresh and cryopreserved tissue-antigen-matched and 
mismatched osteochondral allografts in dogs. J Bone Joint Surg Am 1989;71:1297-307. 
102 
 
64. Tomford WW, Duff GP, Mankin HJ. Experimental freeze-preservation of 
chondrocytes. Clinical Orthopaedics and Related Research 1985:11-4. 
65. Ohlendorf C, Tomford WW, Mankin HJ. Chondrocyte survival in cryopreserved 
osteochondral articular cartilage. J Orthop Res 1996;14:413-6. 
66. Rozen B, Brosh T, Salai M, Herman A, Duckiewicz I. The effects of prolonged deep 
freezing on the biomechanical properties of osteochondral allografts. Cell and Tissue 
Banking 2009;10:27-31. 
67. Acosta CA, Izal I, Ripalda P, Forriol F. Cell viability and protein composition in 
cryopreserved cartilage. Clinical Orthopaedics and Related Research 2007;460:234-9. 
68. Jomha NM, Law GK, McGann LE. Storage of porcine articular cartilage at high 
subzero temperatures. Cell and Tissue Banking 2006;7:55-60. 
69. Carsi B, Lopez-Lacomba JL, Sanz J, Marco F, Lopez-Duran L. Cryoprotectant 
permeation through human articular cartilage. Osteoarthritis Cartilage 2004;12:787-92. 
70. Jomha NM, Weiss AD, Fraser Forbes J, Law GK, Elliott JA, McGann LE. 
Cryoprotectant agent toxicity in porcine articular chondrocytes. Cryobiology 
2010;61:297-302. 
71. Malinin TI, Wagner JL, Pita JC, Lo H. Hypothermic storage and cryopreservation 
of cartilage. An experimental study. Clinical Orthopaedics and Related Research 
1985:15-26. 
72. Csonge L, Bravo D, Newman-Gage H, et al. Banking of osteochondral allografts, 
Part II. Preservation of chondrocyte viability during long-term storage. Cell and Tissue 
Banking 2002;3:161-8. 
73. Aubin PP, Cheah HK, Davis AM, Gross AE. Long-term followup of fresh femoral 
osteochondral allografts for posttraumatic knee defects. Clinical Orthopaedics and 
Related Research 2001:S318-27. 
74. Sammarco VJ, Gorab R, Miller R, Brooks PJ. Human articular cartilage storage in 
cell culture medium: guidelines for storage of fresh osteochondral allografts. 
Orthopedics 1997;20:497-500. 
75. McCulloch PC, Kang RW, Sobhy MH, Hayden JK, Cole BJ. Prospective evaluation 
of prolonged fresh osteochondral allograft transplantation of the femoral condyle: 
minimum 2-year follow-up. The American Journal of Sports Medicine 2007;35:411-20. 
76. Pearsall AW, Tucker JA, Hester RB, Heitman RJ. Chondrocyte viability in 
refrigerated osteochondral allografts used for transplantation within the knee. The 
American Journal of Sports Medicine 2004;32:125-31. 
77. Williams SK, Amiel D, Ball ST, et al. Prolonged storage effects on the articular 
cartilage of fresh human osteochondral allografts. The Journal of Bone and Joint Surgery 
2003;85:2111-20. 
78. Pennock AT, Wagner F, Robertson CM, Harwood FL, Bugbee WD, Amiel D. 
Prolonged storage of osteochondral allografts: does the addition of fetal bovine serum 
improve chondrocyte viability? The Journal of Knee Surgery 2006;19:265-72. 
79. Kwan MK, Wayne JS, Woo SL-Y, Field FP, Hoover J, Meyers MH. Histological and 
biomechanical assessment of articular cartilage from stored osteochondral shell 
allografts. Journal of Orthopaedic Research 1989;7:637-44. 
103 
 
80. Wayne JS, Amiel D, Swan MK, Woo SL-Y, Fierer A, Meyers MH. Long-term storage 
effects on canine osteochondral allografts. Acta Orthopaedica Scandinavica 
1990;61:539-45. 
81. Amiel D, Harwood FL, Hoover JA, Meyers M. A histological and biochemical 
assessment of the cartilage matrix obtained from in vitro storage of osteochondral 
allografts. Connect Tissue Res 1989;23:89-99. 
82. Schachar NS, Cucheran DJ, McGann LE, Novak KA, Frank CB. Metabolic activity of 
bovine articular cartilage during refrigerated storage. J Orthop Res 1994;12:15-20. 
83. Oates KM, Chen AC, Young EP, Kwan MK, Amiel D, Convery FR. Effect of tissue 
culture storage on the in vivo survival of canine osteochondral allografts. J Orthop Res 
1995;13:562-9. 
84. Lang CJ, Heckmann JG, Neundorfer B. Creutzfeldt-Jakob disease via dural and 
corneal transplants. J Neurol Sci 1998;160:128-39. 
85. Billette de Villemeur T, Deslys JP, Pradel A, et al. Creutzfeldt-Jakob disease from 
contaminated growth hormone extracts in France. Neurology 1996;47:690-5. 
86. Teng MS, Yuen AS, Kim HT. Enhancing osteochondral allograft viability: effects of 
storage media composition. Clinical Orthopaedics and Related Research 2008;466:1804-
9. 
87. Allen RT, Robertson CM, Pennock AT, et al. Analysis of stored osteochondral 
allografts at the time of surgical implantation. The American Journal of Sports Medicine 
2005;33:1479-84. 
88. Rohde RS, Studer RK, Chu CR. Mini-pig fresh osteochondral allografts deteriorate 
after 1 week of cold storage. Clinical Orthopaedics and Related Research 2004:226-33. 
89. Robertson CM, Allen RT, Pennock AT, Bugbee WD, Amiel D. Upregulation of 
apoptotic and matrix-related gene expression during fresh osteochondral allograft 
storage. Clinical Orthopaedics and Related Research 2006;442:260-6. 
90. Linn MS, Chase DC, Healey RM, Harwood FL, Bugbee WD, Amiel D. Etanercept 
Enhances Preservation of Osteochondral Allograft Viability. The American Journal of 
Sports Medicine 2011. 
91. Bae JY, Matsumura K, Wakitani S, Kawaguchi A, Tsutsumi S, Hyon SH. Beneficial 
storage effects of epigallocatechin-3-o-gallate on the articular cartilage of rabbit 
osteochondral allografts. Cell Transplant 2009;18:505-12. 
92. Pylawka TK, Virdi AS, Cole BJ, Williams JM. Reversal of suppressed metabolism in 
prolonged cold preserved cartilage. J Orthop Res 2008;26:247-54. 
93. Pallante AL, Bae WC, Chen AC, Gortz S, Bugbee WD, Sah RL. Chondrocyte viability 
is higher after prolonged storage at 37 degrees C than at 4 degrees C for osteochondral 
grafts. The American Journal of Sports Medicine 2009;37:24S-32S. 
94. Bian L, Stoker AM, Marberry KM, Ateshian GA, Cook JL, Hung CT. Effects of 
dexamethasone on the functional properties of cartilage explants during long-term 
culture. The American Journal of Sports Medicine 2010;38:78-85. 
95. McCarty WJ, Pallante AL, Rone RJ, Bugbee WD, Sah RL. The proteoglycan 
metabolism of articular cartilage in joint-scale culture. Tissue Eng Part A 2010;16:1717-
27. 
104 
 
96. Meyers MH, Akeson W, Convery FR. Resurfacing of the knee with fresh 
osteochondral allograft. J Bone Joint Surg Am 1989;71:704-13. 
97. Garrett JC. Fresh osteochondral allografts for treatment of articular defects in 
osteochondritis dissecans of the lateral femoral condyle in adults. Clinical Orthopaedics 
and Related Research 1994:33-7. 
98. Ghazavi MT, Pritzker KP, Davis AM, Gross AE. Fresh osteochondral allografts for 
post-traumatic osteochondral defects of the knee. J Bone Joint Surg Br 1997;79:1008-
13. 
99. Chu CR, Convery FR, Akeson WH, Meyers M, Amiel D. Articular cartilage 
transplantation. Clinical results in the knee. Clinical Orthopaedics and Related Research 
1999:159-68. 
100. Gross AE, Shasha N, Aubin P. Long-term followup of the use of fresh 
osteochondral allografts for posttraumatic knee defects. Clinical Orthopaedics and 
Related Research 2005:79-87. 
101. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of 
sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 
1986;883:173-7. 
102. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline 
in biological tissues. Clin Biochem 1996;29:225-9. 
103. Breshears LA, Cook JL, Stoker AM, Fox DB, Luther JK. The effect of uniaxial cyclic 
tensile load on gene expression in canine cranial cruciate ligamentocytes. Vet Surg 
2010;39:433-43. 
 
 
 
